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ABSTRACT 
The intestine is a major site of immune activity, and disturbances in the 
balance of proinflammatory and anti-inflammatory signals can lead to difficult 
and chronic diseases, like inflammatory bowel diseases, manifesting in 
uncontrolled inflammation in intestine. Local intestinal renin-angiotensin 
system (RAS) and glucocorticoid synthesis are recently uncovered complex 
mechanisms participating in the pathophysiology of intestinal diseases. These 
systems can offer new therapy options, either by repurposing well-known 
drugs like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers or by novel innovations like mesenchymal stromal cell 
therapy.  
The aim of this thesis was to investigate intestinal RAS and glucocorticoid 
production in intestinal inflammation and examine potential treatments with 
the focus on these two systems. RAS and glucocorticoid production and their 
possible interactions in intestine were characterized in a dextran sodium 
sulfate (DSS)-induced experimental colitis model using in vitro stimulations 
and inhibition of RAS in vivo. Glucocorticoid synthesis and ACE shedding 
were investigated as the release of corticosterone and ACE protein from live 
tissue to incubation media in vitro. The effects of ACE inhibitor, captopril, and 
ACE-inhibiting milk-derived bioactive tripeptide, Ile-Pro-Pro, were examined 
on intestinal RAS and glucocorticoid synthesis. ACE inhibitor, enalapril, and 
angiotensin II receptor blocker, losartan, were tested alone and in 
combination in alleviation of colitis. Finally, freshly cultivated and 
cryopreserved platelet-lysate expanded mesenchymal stromal cells were 
compared and their feasibility was examined in the treatment of colitis.  
Enalapril and losartan were effective at alleviating colitis and lessening 
inflammation on their own but were without synergistic effects, supporting 
their potential to be investigated in clinical trials. MSC treatments proved 
feasible and without adverse effects, and freshly cultivated MSC treatments 
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had a modest anti-inflammatory effect reflected by reduction in 
proinflammatory cytokine levels. We found a specific induction of ACE 
ectodomain shedding in distal colon, the most affected region in DSS-induced 
colitis, and in proximal colon following a high DSS dose. ACE shedding could 
be downregulated by cryopreserved MSCs and an ACE-inhibiting tripeptide 
Ile-Pro-Pro treatment in vivo. These data imply that cell-surface ACE levels are 
actively regulated in intestinal inflammation, which could be a feedback 
mechanism to reduce the proinflammatory angiotensin II (Ang II) signaling. 
Ang II induced glucocorticoid production in small intestine incubations in 
vitro, thus implying of an anti-inflammatory property in Ang II signaling. We 
suggest that Ang II enhances the TNFα-mediated induction of glucocorticoid 
production during intestinal inflammation. In vitro or in vivo inhibition of Ang 
II production or signaling did not modulate intestinal glucocorticoid 
production, although captopril abolished the gene expression of the rate-
limiting enzyme of glucocorticoid synthesis, Cyp11b1, in vivo.  
INTRODUCTION 
 
12 
 
1 INTRODUCTION 
Inflammation is a vital process to protect organisms from pathogens and 
injuries. It is orchestrated by the immune system, which consists of highly 
specified organs and cells, leukocytes, which function in concert with the host 
tissues to maintain homeostasis between self and the outside world. Majority 
of this contact takes place in the intestine, where immune system must 
discriminate appropriately between dietary antigens, commensal bacteria and 
pathogens. Failure to control inflammation contributes to the pathogenesis of 
plethora of disorders and diseases.  
Inflammatory bowel diseases (IBD) cause chronic inflammation of the 
intestine. They are a major disease burden in the Western world and their 
prevalence is increasing in the developing countries together with changing 
lifestyle (Ng et al., 2018). The processes leading to aberrant inflammation of 
the intestine in IBD are complex and treatments target them with anti-
inflammatory and immunomodulatory drugs, and biologics to block cytokine 
signaling or leukocyte homing and adhesion. Many of the current therapies 
cause difficult adverse effects and drug resistance, raising a need for new 
treatment options.  
Renin-angiotensin system (RAS) is a critical regulator of blood pressure, but in 
addition it participates in several physiological and pathophysiological 
functions locally in intestine including inflammation, fibrosis and apoptosis 
(Fyhrquist and Saijonmaa, 2008). RAS activity can be targeted with ACE 
inhibitors and angiotensin II receptor blockers, which have been efficient at 
treating colitis in preclinical studies (Jahovic et al., 2005). Mesenchymal 
stromal cell therapy is a new treatment option for IBD, but the cell origin and 
culture conditions affect their properties and potency (Gregoire et al., 2017), 
prompting thorough evaluation of feasible manufacturing strategies. 
Glucocorticoids are anti-inflammatory steroid hormones mainly produced by 
the adrenal cortex, but also locally in intestine, where they participate in 
INTRODUCTION 
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maintaining immune homeostasis (Cima et al., 2004). Inflammation in the 
intestine stimulates local corticosterone production, but there are 
disturbances in the process in IBD patients (Coste et al., 2007). 
The studies in this thesis focused on RAS in intestinal inflammation. As RAS 
and glucocorticoids participate in opposite processes of inflammation, we 
sought to elucidate the possible interactions of RAS and glucocorticoids and 
investigate them in a setting of intestinal inflammation. We tested treatments 
for intestinal inflammation with commonly used antihypertensive drugs 
inhibiting RAS at different levels, and cell therapy using mesenchymal stromal 
cells, in a dextran sodium sulfate mouse model of colitis. 
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2 REVIEW OF THE LITERATURE 
2.1 Intestine and inflammation 
Intestinal homeostasis 
Intestine is responsible for fluid and nutrient absorption, but also functions as 
a barrier between the organism and its environment, and thus is a major site 
of immune system. Intestinal immune system is in constant contact with 
dietary and microbial antigens, which results in a permanent state of benign 
immune activity in the intestine (MacDonald et al., 2011). This constitutive 
immune activation is termed immune homeostasis, and its purpose is to 
maintain tolerance to commensal bacteria and avoid overexaggerated immune 
responses while simultaneously preventing microbial overgrowth (Abraham 
and Medzhitov, 2011; MacDonald et al., 2011). Immune system has several ways 
to detect luminal antigens and train immune cells to maintain homeostasis, 
which is vital for the wellbeing of the organism, as disruption of homeostasis 
is thought to be one factor facilitating destructive chronic inflammation 
(Okumura and Takeda, 2017). 
Intestinal epithelium (Figure 1) and mucus form the first line of defense 
against luminal microbes, antigens and toxic agents. Epithelial cells form at 
the base of intestinal crypts and migrate towards surface of the lumen and 
create a rapidly renewing physical barrier due to their tight junctions, which 
prevent luminal antigens and microbes from entering the mucosa (Goll and 
van Beelen Granlund, 2015). Goblet cells of the epithelium produce a 
protecting mucus layer which limits epithelial contact to harmful microbes 
(Johansson et al., 2011). Most of the epithelial cells are enterocytes which 
participate in sensing of luminal and mucosal antigens, antigen delivery to 
antigen-presenting cells and mediation of tolerance to commensal bacteria 
(Goll and van Beelen Granlund, 2015; MacDonald et al., 2011; Snoeck et al., 
2005). Enteroendocrine cells sense luminal composition, relay signals by 
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secreting hormones and regulate the function of other cells (Garrett et al., 
2010). Paneth cells and microfold cells (M cells) reside mainly in the small 
intestine and participate in luminal antigen sensing. Paneth cells produce 
antimicrobial agents and M cells deliver antigens to antigen-presenting cells. 
Intraepithelial lymphocytes reside between epithelial cells. (Garrett et al., 
2010; Goll and van Beelen Granlund, 2015; MacDonald et al., 2011) 
 
Figure 1. Composition of the cell types in intestinal epithelium that contribute to immune 
homeostasis. Modified from Okumura and Takeda, 2017. 
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Sensing of microbial antigens in epithelial and immune cells is mediated by 
pattern-recognition receptors, like Toll-like receptors and nucleotide-binding 
oligomerization domain-containing proteins. They reside on the cellular 
membrane or lysosomes of phagocytotic cells, and mediate either anti-
inflammatory or proinflammatory responses depending on receptor location 
and intensity of the signal. In normal conditions, epithelial and antigen-
presenting cells secrete anti-inflammatory and immunosuppressive 
transforming growth factor-β (TGF-β), prostaglandin E2 (PGE2) and 
interleukin(IL)-10 to maintain tolerance to commensal bacteria and 
downregulate inflammatory processes. (Garrett et al., 2010; Goll and van 
Beelen Granlund, 2015; MacDonald et al., 2011) 
Immune cells are abundant both in epithelium and lamina propria. 
Intraepithelial lymphocytes reside between epithelial cells and participate in 
maintaining epithelial barrier and immune homeostasis. Lamina propria 
contains a large population of leukocytes, namely macrophages, dendritic cells 
and T cells. Dendritic cells can penetrate the epithelium to identify luminal 
antigens and present them to T cells in Peyer’s patches or mesenteric lymph 
nodes, which are specialized lymphoid tissues of the intestine, and thus 
maintain tolerance to commensal bacteria. The resident macrophages and T 
cells display only partial capacity for activation by inflammatory stimuli. 
Resident intestinal macrophages phagocytose microbes and their products, 
and apoptotic epithelial cells, thus clearing excess lamina propria antigens, 
and produce anti-inflammatory cytokines to regulate other immune cells 
(Denning et al., 2007), and stimulate renewal of epithelium by secreting PGE2 
(Bain and Mowat, 2014). A population of anti-inflammatory resident T cells 
display similar reduced activation of T-cell signaling via T-cell receptor and 
suppress immune activation. (Garrett et al., 2010; MacDonald et al., 2011) 
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Intestinal inflammation 
Inflammation is an inherent process to remove pathogenic microbes, toxins, 
and damaged cells and enable wound repair. Acute inflammation occurs at the 
immediate appearance of tissue damage or pathogens as resident immune 
cells release proinflammatory mediators to facilitate vasodilation, increased 
vascular permeability, extravasation of leukocytes, mainly neutrophils and 
macrophages, and blood coagulation. The resulting influx of plasma and 
immune cells to the affected tissue leads to edema, intensifying of 
proinflammatory signals and phagocytosis of pathogens and cell debris, 
increased sensation of pain, and activation of complement system if pathogens 
are present. When the initial inflammatory stimulus is cleared, the 
proinflammatory signaling ceases and anti-inflammatory mediators are 
produced, and the inflammation resolves. Inability to clear the initial stimulus, 
or dysregulation of inflammation and its resolution leads to chronic 
inflammation manifesting in tissue damage, hypoxia, and fibrosis. Acute and 
chronic inflammation are distinctive immune cell and cytokine profiles. 
(Gilroy and De Maeyer, 2015) 
In the intestine, disruption of the epithelial barrier and the subsequent 
translocation of bacteria or their antigens into the intestinal mucosa trigger 
inflammatory processes (Kiesler et al., 2015; MacDonald et al., 2011). Antigen-
presenting cells and intestinal epithelium, in response to contact with 
pathogens at their basolateral surface, signal inflammation by expressing 
chemokines and cytokines, which attract and activate immune cells and 
directly activate lymphocytes (Goll and van Beelen Granlund, 2015; Okumura 
and Takeda, 2017). Epithelial cells and endothelium of venules in intestine 
express cell adhesion molecules, like CC chemokine ligand (CCL) 25 and 
mucosal addressin cell adhesion molecule-1 (MAdCAM-1), to attract T cells in 
response to inflammatory stimuli. The newly extravasated lymphocytes are 
activated and participate in immune reactions, produce more 
proinflammatory cytokines and regulate intestinal permeability, which in part 
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can lead to increased translocation of pathogens to mucosa and increased 
immune cell recruitment and activation. Inappropriate regulation in these 
functions can lead to an exaggerated and uncontrolled proinflammatory cycle, 
like seen in inflammatory bowel diseases (IBD). (MacDonald et al., 2011) 
 
Inflammatory bowel diseases 
Inflammatory bowel diseases are chronic and multifactorial diseases, which 
manifest in recurring and often debilitating inflammation of the 
gastrointestinal tract (Ramos and Papadakis, 2019). The two main forms of 
IBD are Crohn’s disease (CD) and ulcerative colitis (UC). In UC, the 
inflammation and the associated ulcers are limited to the lining of the large 
intestine. In CD, the inflammation can affect any part of the gastrointestinal 
tract but is most common in ileum, and the inflammation and damage may 
reach deeper into the tissue forming difficult to treat fistulas. The incidence of 
IBD is increasing, especially in the developed countries (Ramos and Papadakis, 
2019). 
Both genetic and environmental factors contribute to pathogenesis of IBD. 
Genetic susceptibility can be linked to various aspects of mucosal protection 
and immune activation and regulation (Ramos and Papadakis, 2019). 
Microbial dysbiosis, which is promoted by Western lifestyle can enrich 
bacterial species, which weaken the mucosal barrier. Disruption of the 
epithelial barrier, provoked by either genetic factors or altered microbiome, is 
a critical step for the development of aberrant inflammation, and can lead to 
inappropriate immune reactions to commensal bacteria. Impaired immune 
responses, including macrophage activation and recruitment of neutrophils, 
allow bacterial translocation to mucosa in CD, whereas overemphasized T-cell 
response leads to overexaggerated inflammation in IBD. Naïve T helper (Th) 
cells can differentiate to various distinctive subsets, including Th1, Th2, Th17 
and regulatory T cells (Tregs), according to their differentiation environment. 
REVIEW OF THE LITERATURE 
 
19 
 
Unlike cytotoxic T cells which directly induce apoptosis of infected cells, Th 
cells secrete cytokines and augment the function of other immune cells. 
Phagocytotic immune cells promote Th1 cell differentiation in response to 
intracellular pathogens, whereas Th2 differentiation is initiated to respond to 
extracellular pathogens. Th17 cells function at mucosal surfaces and attract 
other immune cells during bacterial and fungal infections. Tregs are a subtype 
of anti-inflammatory Th cells which suppresses immune responses and 
participates in maintaining homeostasis. CD and UC have typical distortions 
in T-cell populations. T cells of lamina propria of IBD patients are resistant to 
apoptosis (Gregoire et al., 2017). Regulatory T cells are under-represented in 
IBD, and inflammation is mediated by Th1 and Th17 type cells in CD and Th2 
cells in UC, resulting in distinct cytokine profiles in the intestine.  (Gregoire et 
al., 2017; Kmiec et al., 2017; Ramos and Papadakis, 2019)  
Pharmacological treatments for IBD are aimed to achieve and maintain 
remission in patients, improve quality of life, and avoid malignancies and 
surgical treatments (Sales-Campos et al., 2015). Conventional treatments 
include anti-inflammatory aminosalicylates and corticosteroids, 
immunosuppressive thiopurines and methotrexate, and antibiotics. The most 
effective of these treatment options, thiopurines and corticosteroids, may 
cause difficult side effects limiting their use. Biologic drugs include antibodies 
against proinflammatory cytokines, TNFα and IL-12, and leukocyte adhesion 
molecules. Although effective, they are also expensive, and development of 
drug resistance is common. Novel therapies that have gained approval for 
treatment of IBD include cell therapy using mesenchymal stromal cells, and 
Janus kinase (JAK) inhibitors. 
 
Experimental colitis models 
Several experimental models of colitis have been developed for mice and rats 
for the study of human IBD. Although none of them can quite recapitulate the 
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complexity of human disease, they are valuable tools in the study of 
mechanisms of IBD and colitis (Chassaing et al., 2014). Among the most 
common models are the chemically induced colitis models, including dextran 
sodium sulfate (DSS)- and trinitrobenzene sulfonic acid-induced colitis. 
Immune-relevant models include genetic IL-10 knockout model and infectious 
models. Examples of the commonly used colitis models are listed in Table 1. 
(Kiesler et al., 2015) 
 
Table 1. Examples of chemically induced, genetic, infectious and other colitis models. 
SAMP1/Yit(Fc) is a mouse strain which develops a spontaneous ileitis. DSS = Dextran sodium 
sulfate, IL-10 = Interleukin 10, Muc2 = Mucin 2, TNBS = Trinitrobenzene sulfonic acid.  
Chemical models Mechanism Reference 
DSS Epithelial barrier defect Okayasu et al., 1990 
TNBS Excessive T-cell response Neurath et al., 1995 
Piroxicam Oxidative stress Berg et al., 2002 
Oxazolone Excessive T-cell response Boirivant et al., 1998 
Acetic Acid Epithelial barrier defect MacPherson and Pfeiffer, 1978 
Genetic models Mechanism Reference 
Muc2 Epithelial barrier defect, spontaneous colitis 
Velcich et al., 2002, Van der 
Sluis et al., 2006 
SAMP1/Yit(Fc) Spontaneous colitis Kosiewicz et al., 2001 
   
Infectious models Mechanism Reference 
IL-10 knockout Regulatory and effector T cell imbalance Berg et al., 1996 
Salmonella spp. Infectious colitis Barthel et al., 2003 
Other models Mechanism Reference 
Adherent–invasive Escherichia coli Infectious colitis Boudeau et al., 1999 
Adoptive transfer Regulatory and effector T cell imbalance Powrie et al., 1993 
 
2.1.4.1 Dextran sodium sulfate model 
DSS-induced colitis is one of the most used experimental colitis models of UC 
due to its simplicity and reproducibility (Eichele and Kharbanda, 2017), and is 
the model of choice in this thesis. DSS used in induction of colitis is a polymer 
chain consisting of (1 -> 6)-linked dextran chain with two to three sulphate 
moieties at the 2nd, 3rd or 4th carbons (Figure 2). Polymers weighing 
approximately 40 kDa are most colitogenic (Kitajima et al., 2000). DSS is a 
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stable polymer (Kitajima et al., 2002) which can be administered to animals in 
drinking fluid as 1-5% solution for a few days or longer to induce acute colitis 
(Okayasu et al., 1990). Cycles of low-concentration DSS and pure water 
scheme can be used to induce chronic colitis and eventually colorectal cancer 
(Perše and Cerar, 2012). 
 
 
Figure 2. Chemical formula of dextran sodium sulfate used in colitis induction. 
 
DSS is toxic to intestinal epithelial cells (Eichele and Kharbanda, 2017), and it 
increases intestinal permeability by loss of tight junction proteins and disrupts 
the epithelial barrier by increasing apoptosis rate in colonic epithelium 
(Mennigen et al., 2009; Poritz et al., 2007). The epithelial damage exposes 
mucosa to luminal bacteria and antigens and causes inflammation that is 
largely mediated by innate immunity but involves adaptive immunity as well 
(Kiesler et al., 2015; Perše and Cerar, 2012). Therefore, DSS model is especially 
useful for studying macrophage and neutrophil functions, mechanisms of 
innate immunity and epithelial barrier function in the involvement of 
intestinal inflammation. Bacterial translocation is essential to DSS-induced 
colitis, and in addition, it causes dysbiosis to some extent (Kiesler et al., 2015; 
Perše and Cerar, 2012). The damage in acute colitis can be lessened with 
antibiotics (Hans et al., 2000) and it is much milder in germ-free animals 
(Hudcovic et al., 2001). DSS induces the production of several 
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proinflammatory cytokines, e.g. tumor necrosis factor-α (TNF-α), IL-1β, 
interferon-γ (IFN-γ), IL-10, and IL-12 (Yan et al., 2009), of which IL-1β is the 
primary proinflammatory cytokine (Kiesler et al., 2015). DSS is taken up by 
macrophages in the mucosa and delivered to mesentery lymph node and 
eventually excreted to feces and urine (Perše and Cerar, 2012). 
DSS induces diarrhea, weight loss, damage in the colon mucosa and bleeding. 
The magnitude of the damage depends on the dose and duration of 
administration. In acute inflammation, histopathological changes include 
crypt and surface epithelial damage, disappearance of goblet cells or crypts, 
ulceration and erosion of mucosa and inflammatory infiltrate of neutrophils in 
mucosa and submucosa. The typical changes in acute colitis are presented in 
Table 2. Chronic inflammation develops over a few weeks after the initial DSS 
administration and can be transmural. (Perše and Cerar, 2012) The 
susceptibility and involvement of T cells in DSS colitis is strain dependent. 
C57BL/6 mice develop more severe colitis than BALB/c and develop chronic 
colitis after DSS withdrawal, whereas BALB/c mice eventually recover (Melgar 
et al., 2005), making different strains more suitable in studying the healing 
process or chronic colitis. Strains also differ in their adaptive immunity 
response to DSS. Acute DSS colitis in C57BL/6 is polarized to Th1 and in 
BALB/c to Th2/Th17 response (Yang et al., 2017). 
 
Table 2. Typical phenotypical, histopathological and biochemical changes in acute DSS colitis. 
IFNγ = Interferon-γ, IL = Interleukin, TNFα = Tumor necrosis factor-α. 
Macroscopic changes Histopathological changes Biochemical alterations 
Weight ↓ Loss of crypts and goblet cells IL-1β, TNFα, IFNγ, IL-10, IL-12 ↑ 
Diarrhea  Apoptosis of epithelial cells Tight junction proteins ↓ 
Intestinal permeability ↑ Erosions and ulcerations Myeloperoxidase activity ↑ 
Inflammatory cell infiltrate 
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2.1.4.2 Other colitis models 
Trinitrobenzene sulfonic acid (TNBS) colitis model is another commonly used 
chemically induced colitis model. TNBS is a hapten, which renders proteins 
immunogenic to the host when administered intrarectally, and induces 
diarrhea, weight loss and infiltration of neutrophils and macrophages 
(Neurath et al., 1995). TNBS colitis has a major Th1-mediated adaptive 
immunity component, but innate immunity reactions are also necessary for its 
induction. Compared to DSS colitis, TNBS induces more prominent Th cell 
infiltration, and the inflammation is generally transmural, leading to fibrosis 
in its chronic form. The similarity of cytokine responses and fibrotic activity 
between TNBS colitis and CD is why it is often used as model for CD. 
Oxazolone is another hapten given intrarectally (Boirivant et al., 1998), which 
induces natural killer cell-mediated mucosal inflammation by cytotoxic 
activity to intestinal epithelial cells and increase of intestinal permeability by 
production of IL-13 and can be used as a model of UC. (Antoniou et al., 2016; 
Kiesler et al., 2015) 
In adoptive transfer colitis (Powrie et al., 1993), naïve Th cells are transferred 
to immunodeficient mice without capacity to produce mature T or B cells. 
Without regulatory T cells to counterbalance the actions of Th cells, mice 
develop colitis, which makes this model suitable to study immunoregulation, 
especially regulatory T cells.  IL-10 knockout mice develop spontaneous colitis 
due to disturbed immunoregulation, which can further be aggravated by 
piroxicam (Berg et al., 1996; Berg et al., 2002). Piroxicam and indomethacin are 
non-steroidal anti-inflammatory drugs, which can also be used on their own to 
induce colitis. (Kiesler et al., 2015; Valatas et al., 2015) 
Rectal administration of acetic acid causes epithelial injury and ulceration 
(MacPherson and Pfeiffer, 1978) and can be useful in studying mechanisms 
involving reactive oxygen species. Several other less widely used chemically 
induced (e.g. dinitrobenzene sulfonic acid), genetic (mucin 2 knockout) and 
infectious (Salmonella spp.) models exist to study intestinal inflammation. 
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Most models require an intact microbiome to develop, as germ-free mice are 
resistant to many colitogenic factors, highlighting the significance of disturbed 
host-microbial interactions and epithelial barrier function in intestinal 
inflammation. (Kiesler et al., 2015; Low et al., 2013) 
 
 
Intestine acts as a physical and an immunological 
barrier against microbes and dietary antigens, 
protecting the host from pathogens, while mediating 
tolerance to commensal bacteria and harmless antigens. 
This process is called immune homeostasis and its 
disruption can lead to inappropriate and chronic 
immune activation with devastating consequences to 
the host. 
 
 
REVIEW OF THE LITERATURE 
 
25 
 
2.2 Renin-Angiotensin system 
The renin-angiotensin system (RAS) is a complex network which regulates 
various physiological and pathophysiological functions in several organs 
(Fandriks, 2011; Paul et al., 2006). Systemic RAS is a critical regulator of blood 
pressure and it is involved in inflammation, apoptosis and fibrosis (Paul et al., 
2006) (Figure 3). Angiotensinogen is the precursor of all peptide hormones in 
RAS, which is mainly produced in the liver. Kidneys produce and secrete a 
serine protease renin which cleaves ten N-terminal amino acid residues from 
angiotensinogen to produce angiotensin I (Ang I) (Asp-Arg-Val-Tyr-Ile-His-
Pro-Phe-His-Leu). RAS regulates blood-pressure via the classical RAS pathway, 
in which angiotensin-converting enzyme (ACE), expressed richly in 
pulmonary vascular endothelium, cleaves two C-terminal residues from 
angiotensin I to form angiotensin II (Ang II). Ang II acts through G-protein 
coupled receptors angiotensin II receptor 1 (AT1R) and to a lesser extent 
angiotensin II receptor 2 (AT2R). AT1R signaling facilitates an increase in 
blood pressure by direct and indirect fluid retention in the kidney by sodium 
excretion and stimulation of aldosterone secretion, and induces 
vasoconstriction in the vascular smooth muscle cells, especially in the 
splanchnic circulation (Fandriks, 2011). AT1R signaling leads to activation of 
nuclear factor-kappa B (NF-κB), the master regulator of inflammatory 
processes, leading to cytokine production, in several organs, leukocyte 
recruitment, apoptosis, cell proliferation and fibrosis. AT2R opposes the 
effects of AT1R and mediates vasodilatation, fluid excretion in kidney and 
intestine, and antiproliferation. In the alternative RAS pathway, Ang II is 
cleaved into angiotensin 1-7 (Ang 1-7) by angiotensin-converting enzyme 2 
(ACE2), which is partially homologous with ACE but has distinct targets. Ang 
1-7 acts through Mas receptor which facilitates similar effects as AT2R, thus 
also opposing the effects of AT1R signaling. ACE2 can also counter the effects 
of classical RAS by cleaving angiotensin I into angiotensin 1-9 which is further 
processed into Ang 1-7 by ACE and neprilysin (Fandriks, 2011). In addition to 
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these factors, many other enzymes produce and inactivate various less-known 
angiotensin peptides that act via their own receptors. (Fleming, 2006; 
Fyhrquist and Saijonmaa, 2008; Lavoie and Sigmund, 2003; Paul et al., 2006)  
ACE has diverse known, and undoubtedly unknown, substrates relevant to 
function of RAS locally in various tissues. RAS is linked to kinin-kallikrein 
system in so that kallikrein can activate prorenin and ACE can inactivate the 
vasodilating peptide bradykinin. An alternative way of producing Ang II is by 
chymase, which can cleave Ang I into Ang II in various tissues. In addition to 
its enzyme activity, ACE acts as a surface receptor, which is activated by at 
least bradykinin as its natural substrate. Activation of ACE receptor involves 
dimerization of ACE and intracellular phosphorylation by casein kinase 2, 
which promotes retention of ACE at the cellular membrane (Kohlstedt et al., 
2006; Kohlstedt et al., 2002), Activation of ACE receptor function leads to 
activation of c-Jun N-terminal kinase and subsequently c-Jun transcription 
factor, which upregulates various target genes, including cyclo-oxygenase-2 
and ACE itself (Kohlstedt et al., 2004; Kohlstedt et al., 2005). (Bernstein et al., 
2013; Fleming, 2006) 
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Figure 3. A simplified scheme of the main classical and alternative renin-angiotensin system 
pathways and effects. (Modified from Holappa et al., 2017) 
 
Soluble and membrane-bound angiotensin-converting 
enzyme 
ACE is a membrane-bound protein, which exists in somatic form in 
endothelial, epithelial and immune cells, and in germinal form only in 
spermatozoa (Ehlers et al., 2012). In addition, ACE can be enzymatically 
solubilized or shedded from the cell surface and can be found in plasma and 
other body fluids, but the membrane-bound form is considered more 
important for blood pressure regulation. In fact, the purpose of ACE shedding 
is not known, but has been suggested to reduce local production of Ang II by 
the release of the enzyme. However, soluble ACE is still enzymatically active 
and might serve some yet unknown function. The plasma ACE is derived 
mainly from the lung vascular endothelium, where it can be considerably 
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reduced during sepsis and acute lung injury (Orfanos et al., 2000; Votta-Velis 
et al., 2007). Inhibition of ACE, certain inflammatory diseases, like sarcoidosis, 
and lung injury lead to upregulation of soluble ACE in plasma, in which case 
the origin might be monocytic cells (Ehlers et al., 2012; Forslund et al., 1982). 
(Bernstein et al., 2013; Ehlers et al., 2012) 
The somatic ACE consists of two, N- and C-terminal, extracellular domains 
with catalytic sites, a stalk region containing a proteolytic cleavage site near a 
transmembrane region, and a cytoplasmic domain with phosphorylation sites 
(Ehlers et al., 2012). A disintegrin and a metalloprotease 9 (ADAM9) was 
shown to cleave ACE from human umbilical vein endothelial cell membranes 
in response to proinflammatory stimuli, TNFα signaling and NF-κB activation 
(English et al., 2012). Both ACE and ADAM9 are expressed in endothelial cells, 
monocytes and macrophages, and therefore shedding might occur in various 
cell types (English et al., 2012). Active metalloprotease-dependent shedding of 
ACE involves conformational changes due to dephosphorylation of the 
intracellular tail (Kohlstedt et al., 2002), protein kinase C signaling, and is 
possibly dependent on resolution of dimerization of ACE, whereas regulation 
and mechanisms of basal shedding are yet unknown (Balyasnikova et al., 2002; 
English et al., 2012).   
 
Inhibition of renin-angiotensin system 
Due to the crucial role of RAS in the development of hypertension and 
associated cardiovascular diseases, inhibition of Ang II signaling is pivotal in 
the treatment of these diseases.  Two major classes of pharmacologic RAS 
inhibitors are widely used to treat hypertension; ACE inhibitors and 
angiotensin II receptor blockers (ARBs). ACE inhibitors prevent the cleavage 
of Ang I into Ang II, and also bradykinin breakdown. In addition to 
bradykinin, some ACE inhibitors can trigger ACE receptor signaling (Fleming, 
2006). ARBs are antagonists of AT1R and prevent receptor activation and 
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signal transduction without affecting Ang II levels. Third class of RAS 
inhibitors are renin inhibitors, which inhibit the formation of Ang I from 
angiotensinogen. ACE inhibitors and ARBs are generally well-tolerated drugs, 
but common adverse effects include hypotension and hyperkalemia, and 
cough in the case of ACE inhibitors. Rare and serious adverse effects include 
acute renal failure and liver damage, and in some cases, they may cause tissue 
swelling called angioedema, which usually affects tongue or pharynx but is 
also reported to rarely affect the intestine (Malde et al., 2007; Wilin et al., 
2018).  
In addition to pharmacologic compounds, nutrition-derived compounds have 
found to inhibit ACE activity (Jäkälä and Vapaatalo, 2010). Microbial 
fermentation of milk casein by lactic acid bacteria or by enzymatic processing 
produces bioactive peptides with antihypertensive properties, which have 
been verified in clinical trials (Cicero et al., 2013; Turpeinen et al., 2013; Xu et 
al., 2008), but the antihypertensive mechanism of action is not accounted to 
ACE inhibition alone (Majumder and Wu, 2014), and involves vasodilatation 
by increased Ang 1-7 and Mas receptor activation (Ehlers et al., 2011). Ile-Pro-
Pro and Val-Pro-Pro are among these peptides, and they competitively inhibit, 
albeit weakly, ACE with 5 and 9 μM IC50 values, respectively (Lehtinen et al., 
2010; Nakamura et al., 1995). Pharmacological ACE inhibitors captopril, and 
the active metabolite of enalapril, enalaprilat, inhibit ACE with respective IC50 
values of 21 nM (Hooper and Turner, 1987) and 1.94 nM (Ceconi et al., 2007). 
 
Renin-angiotensin system in the intestine 
All the core enzymes and receptors of RAS (renin, angiotensinogen, ACE, 
ACE2, AT1R, AT2R, Mas receptor) are expressed in the gastrointestinal tract 
(Bernardi et al., 2012; Hamming et al., 2004; Hirasawa et al., 2002; Sechi et al., 
1993) (Figure 4), where their functions include involvement in motility, 
transport of fluid, electrolytes, and nutrients, and participation in regulation 
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of inflammation (Fandriks, 2011; Fishlock and Gunn, 1970). Renin is produced 
by goblet cells and excreted into intestinal lumen with mucus in small 
intestine (Shorning et al., 2012). In colon, renin is localized into surface 
epithelium, smooth muscle cells and mesenchymal cells (Hirasawa et al., 
2002). Angiotensinogen is produced locally in vascular smooth muscle cells, 
while Ang I and Ang II localize in epithelial cells especially in the crypts 
(Hume et al., 2016; Shorning et al., 2012). ACE is highly expressed in the brush 
border of small intestine, and in colon in lower quantities in epithelium, 
endothelial cells, and mesenchymal cells (Hirasawa et al., 2002; Shorning et 
al., 2012). Cleavage of ACE has been documented from human small intestine 
(Naim, 1996), but at the brush border the metalloprotease activity leading to 
shedding of ACE has been reported to be low (Oppong and Hooper, 1993). 
Soluble N-terminal domain of ACE has been found in intestinal lumen and is 
potentially processed from ACE post-shedding (Deddish et al., 1994). ACE2 is 
expressed in vascular endothelium, smooth muscle cells and the small 
intestine brush border (Hamming et al., 2004). AT1R is highly expressed in 
enterocytes, as well as vascular endothelium and mesenchymal cells in lamina 
propria (Hirasawa et al., 2002; Shorning et al., 2012). AT2R is expressed at 
much lower quantities, predominantly in the smooth muscle cells and 
vascular endothelium and to an even lesser extent on the luminal membranes 
of endothelial cells, crypts and mesenchymal cells (Hirasawa et al., 2002; Sechi 
et al., 1993). Expression of Mas receptor is low in healthy colon (Khajah et al., 
2016).  
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Renin-angiotensin system in the pathophysiology of 
intestinal inflammation 
RAS is involved in various pathophysiological functions in the progress of 
intestinal inflammation and Ang II is the key proinflammatory factor in these 
processes via AT1R. Ang II production is increased in intestinal inflammation 
(Jaszewski et al., 1990; Khajah et al., 2016), and in some cases its local 
concentration can act as a switch to modulate signaling between physiological 
and pathophysiological conditions (Hornych et al., 1973; Jin et al., 1998). 
Pronounced AT1R signaling leading to NF-κB activation regulates similar 
inflammatory responses in intestine as it does systemically (Garg et al., 2012; 
Lee et al., 2014; Wang et al., 2013). Ang II induces apoptosis and proliferation 
of intestinal epithelial cells, induces adhesion molecule expression in mucosal 
venules leading to leukocyte recruitment, and fibrosis in a healing intestinal 
wall (Garg et al., 2012; Wang et al., 2013). Ang II induces contractions in the 
smooth muscles of the intestine (Fishlock and Gunn, 1970; Garg et al., 2012). 
High concentrations of Ang II inhibit sodium and fluid absorption via AT1R, 
although low concentrations stimulate it via AT2R (Hornych et al., 1973; Jin et 
al., 1998), which likely contributes to diarrhea in intestinal inflammation. 
Additionally, Ang II enhances and activates proinflammatory leukocyte 
functions like cytokine production and cytotoxicity in macrophages and 
neutrophils in vivo (Aki et al., 2010; Khan et al., 2017) and dendritic cells, and T 
cells in vitro, and they all prominently express AT1R on their surface (Khan et 
al., 2017; Meng et al., 2017; Zhang and Crowley, 2013). At least macrophages 
and dendritic cells also express ACE and produce Ang II (Chen et al., 2013b; 
Danilov et al., 2003). 
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Inhibition of renin-angiotensin system in experimental 
colitis 
Due to the extensive role RAS plays in regulation of inflammation, 
pharmacological modulation of Ang II signaling has received considerable 
interest as a potential treatment for intestinal inflammation. In animal 
experiments, ACE inhibitors, captopril, enalapril, enalaprilat and lisinopril, 
(Jahovic et al., 2005; Koga et al., 2008; Lee et al., 2014; Okawada et al., 2016; 
Spencer et al., 2007; Sueyoshi et al., 2013; Wengrower et al., 2004) and 
angiotensin II receptor blockers, losartan and its analogues, valsartan, 
candesartan, olmesartan and telmisartan (Arab et al., 2014; Inokuchi et al., 
2005; Liu et al., 2016; Mizushima et al., 2010; Nagib et al., 2013; Okawada et al., 
2011; Okawada et al., 2016; Santiago et al., 2008; Shi et al., 2016; Wengrower et 
al., 2012) have all alleviated experimental colitis and histological damage in 
DSS, TNBS and IL-10 knockout colitis models (Error! Reference source not f
ound.3). Both ACE inhibition and angiotensin II receptor blockade reduce 
epithelial cell apoptosis and fibrosis in colon (Jahovic et al., 2005; Liu et al., 
2016; Okawada et al., 2011; Spencer et al., 2007; Wengrower et al., 2012; 
Wengrower et al., 2004). On the contrary, inhibition of Mas receptor or 
administration of Ang II exacerbates colitis, but administration of low dose 
Ang 1-7 prevents and ameliorates DSS colitis (Khajah et al., 2016; Shi et al., 
2016).  
The role of endogenous RAS in colitis has also been studied in genetically 
modified animals. Angiotensinogen knockout mice develop milder colitis and 
they have impaired IL-1β and IFN-γ and higher IL-10 production, similar to 
losartan-treated mice (Inokuchi et al., 2005). Also AT1R knockout protects 
mice from DSS colitis and the mice have lower TNFα production than their 
wildtype counterparts (Katada et al., 2008; Mizushima et al., 2010). Conversely, 
renin overexpression dramatically worsens TNBS colitis (Shi et al., 2016). 
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In addition to colitis, local RAS has been studied in context of other diseases 
of the gastrointestinal tract. In a rat model of short-bowel syndrome, ACE 
inhibitors attenuated epithelial cell apoptosis in the small intestine (Wang et 
al., 2013). ACE inhibitor lisinopril, the ARB losartan and Ang 1-7 have 
accelerated the healing of gastric ulcers in rats (Pawlik et al., 2016). 
 
Table 3. Preclinical studies of ACE inhibitors, angiotensin II receptor blockers, and renin 
inhibitors and genetic models in colitis conducted using mice or rats. Mouse strains are 
C57/BL6, AT1R -/- C57BL/6, IL10 -/- C57BL/6, ICR, Agt -/- ICR, and BALB/c. Rat strains are 
Sabra, Sprague-Dawley, and Wistar rats. DAI = disease activity index, DCL = 
deschlorolosartan, DSS = dextran sodium sulfate, L = Losartan, RenTgMK = Mice 
constitutively overexpressing renin, TNBS = Trinitrobenzene sulfonic acid. 
ACE inhibitors 
Treatment Dose Colitis model  Strain Outcome Reference 
Captopril 50 mg/kg/d TNBS  Sabra 
Reduction of DAI, histopathology and 
fibrosis 
Wengrower 
et al., 2004 
Captopril or 
lisinopril 
0.1 or 1 
mg/kg/d TNBS  
Sprague-
Dawley 
Reduction of macroscopic and 
histopathology scores, and collagen 
deposition by captopril 
Jahovic et al., 
2005 
Enalaprilat 14.5 μg/d DSS  C57BL/6 
Improved weight, histopathology, reduced 
apoptosis rate 
Spencer et al., 
2007 
Enalaprilat 
14.5 or 145 
μg/d DSS  C57BL/6 
Increased survival, reduced DAI, 
histopathology and fibrosis 
Koga et al., 
2008 
Enalaprilat 12.5 mg/kg/d Piroxicam  
IL10 -/- 
C57BL/6 
Increased survival, reduced disease score. 
Improved histopathology 
Sueyoshi et 
al., 2013 
Enalapril 
1 or 5 
mg/kg/d DSS  C57BL/6  
Improvement in histopathology, reduced 
NF-κB activation and proinflammatory 
cytokines 
Lee et al., 
2014 
Enalaprilat 25 mg/kg/d DSS  
IL10 -/- 
C57BL/6 
Improved weight and histopathology, 
reduced NF-κB activation and 
proinflammatory cytokines 
Okawada et 
al., 2016 
       
Angiotensin II receptor blockers 
Treatment Dose Colitis model  Strain Outcome Reference 
Valsartan 160 mg/ml DSS & TNBS  
Sprague-
Dawley 
Improved weight, and histopathology and 
macroscopic score in TNBS model, reduced 
diarrhea in DSS model 
Santiago et 
al., 2008 
Candesartan 0.4 mg/kg/d DSS  C57BL/6 
Improved weight, histopathology and TNFα 
in AT1R-/-, improved disease activity and 
body weight by candesartan 
Mizushima et 
al., 2010 
Losartan, 
candesartan, 
deschloro-
losartan 
L/DCL 100 
mg/kg/d 
candesartan 
10 mg/kg/d Piroxicam  C57BL/6 
Improved histopathology and reduced 
epithelial cell apoptosis by all treatments 
Okawada et 
al., 2011 
Losartan 7 mg/kg/d TNBS  Sabra 
Reduced TGF-β-mediated fibrosis by 
losartan 
Wengrower 
et al., 2012 
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Olmesartan 
1, 3 or 10 
mg/kg/d DSS  Wistar 
Improved colon length, histopathology and 
TNFα 
Nagib et al., 
2013 
Telmisartan 10 mg/kg/d TNBS  Wistar 
Improved weight, DAI and macroscopic and 
histopathology scores 
Arab et al., 
2014 
CCG-203025 
(losartan 
analog) 100 mg/kg 
DSS & 
piroxicam  
IL10 -/- 
C57BL/6 
Improved weight and histopathology, 
reduced proinflammatory cytokines in DSS 
model, improved weight in piroxicam 
model 
Okawada et 
al., 2016 
Losartan 10 mg/kg/d TNBS  C57BL/6 
Improved weight and histopathology and 
macroscopic scores, reduced apoptosis 
Liu et al., 
2016 
Losartan 30 μg/kg/d TNBS  ICR 
Milder colitis, impaired IL-1β and IFNγ 
production 
Inokuchi et 
al., 2005 
- - 
Ang II infusion 
+ TNBS  C57BL/6 
Ang II infusion caused more weight loss, 
higher histopathology and macroscopic 
scores, and proinflammatory cytokine 
production.  
Shi et al., 
2016 
Losartan 
11 mg/ml (~15 
mg/kg/d) TNBS  C57BL/7 
Improved weight, histopathology and 
macroscopic scores 
Shi et al., 
2016 
       
Genetic models 
Animal model Treatment Colitis model  Strain Outcome Reference 
Agt -/- - TNBS  Agt -/- ICR 
Improved weight and histopathology, 
impaired IL-1β and IFNγ production 
Inokuchi et 
al., 2005 
AT1R -/- - DSS  
AT1R -/- 
C57BL/6 
Improved weight and histopathology, lower 
TNFα expression and production 
Katada et al., 
2008 
AT1R -/-   DSS  
AT1R -/- 
C57BL/6 
Improved weight, histopathology and TNFα 
in AT1R-/-, improved disease activity and 
body weight by candesartan 
Mizushima et 
al., 2010 
Renin 
overexpression 
Aliskiren 20 
mg/kg/d TNBS  
RenTgMK 
129SV 
Reduced survival, worse histopathologic 
and macroscopic scores, increased 
apoptosis and proinflammatory cytokine 
production in RenTgMK mice. Aliskiren 
treatment improved all parameters. Shi et al, 2016 
       
Others 
Treatment Dose Colitis model  Strain Outcome Reference 
Aliskiren 
3 or 10 
mg/kg/d DSS  C57BL/6 
Improved weight, DAI, macroscopy, and 
histopathology at a dose of 10 mg/kg/d. 
Patel et al., 
2014 
Angiotensin 1-7 
0.01, 0.06, 0.1, 
0.3 or 1 
mg/kg/d DSS  BALB/c 
Doses of 0.01 and 0.06 mg/kg/day improved 
weight and histopathology and macroscopic 
scores 
Khajah et al., 
2016 
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Renin-angiotensin system in inflammatory bowel 
diseases 
RAS is involved in several processes, which are important in the pathogenesis 
of IBD, including inflammation, apoptosis, fibrosis and recruitment of 
immune cells (Fandriks, 2011; Garg et al., 2012). However, compared to the 
accumulating evidence on the importance of RAS in experimental colitis, there 
are precious few studies of RAS in human IBD. Angiotensinogen expression 
was found to be low in ileum of CD patients (Hume et al., 2016). However, Ang 
I and Ang II levels were elevated in intestinal mucosa during active 
inflammation in CD (Jaszewski et al., 1990). Renin expression was increased in 
inflamed lesions of both UC and CD patients (He et al., 2019). Mas receptor 
expression was increased in colons of IBD patients, but inflammation lowered 
its expression, and CD increased ACE2 expression in colon (Garg et al., 2015c). 
Plasma ACE2 concentration and activity, renin and Ang 1-7 levels were higher 
in IBD patients than in healthy control subjects, while ACE and Ang II 
remained unchanged (Garg et al., 2015a; Garg et al., 2015c).  
ACE inhibitors and ARBs are generally well-tolerated drugs and could offer a 
novel treatment option in IBD patients as well, but no controlled trials have 
been conducted on the efficacy of RAS inhibition in IBD, and none are in 
progress according to ClinicalTrials.gov. For now, there are only few clinical 
studies which have investigated ARBs or ACE inhibition in IBD patients. In 
one study, levels of proinflammatory cytokines in mucosal biopsies were 
compared between age and gender matched IBD patients who either were on 
ARB therapy or not (Shi et al., 2016). IBD patients on ARB medication had 
lower gene expression of several proinflammatory cytokines and chemokines, 
including IL-1β, TNFα, IL-6, CCL2 and CXCL8 (encoding IL-8), than those who 
were not taking ARBs (Shi et al., 2016). In one retrospective study, use of ACE 
inhibitors and ARBs in IBD patients was associated with lower risk of 
hospitalization, operations and corticosteroid medication (Jacobs et al., 2019). 
REVIEW OF THE LITERATURE 
 
37 
 
In another similar study, use of ACE inhibitors or ARBs was associated with 
lower disease activity and fewer hospitalizations and need of operations in IBD 
patients (Garg et al., 2015b). Prospective clinical trials are needed to evaluate 
the potential of ACE inhibitors and ARBs in IBD.  
 
Renin-angiotensin system is best known as the main 
regulator of blood pressure, but newly found local 
systems have revealed its role in many other 
physiological and pathophysiological functions. In the 
intestine, RAS is involved in many aspects of 
inflammation, which has prompted investigations on 
the possibility to use RAS inhibitors as treatment for 
intestinal inflammation.  
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2.3 Glucocorticoids 
Glucocorticoids are steroid hormones that are crucial for anti-inflammatory 
immune responses, stimulate gluconeogenesis and fat breakdown for energy. 
Systemic glucocorticoid synthesis takes place in zona fasciculata of adrenal 
cortex in response to humoral control of hypothalamus and anterior pituitary. 
Hypothalamus produces corticotropin-releasing hormone and vasopressin, 
which together induce the pituitary to release adrenocorticotropic hormone 
(ACTH). ACTH activates melanocortin 2 receptor, which induces an increase 
of intracellular cyclic adenosine monophosphate (cAMP) to activate protein 
kinase A. This in turn activates the transcription factor, steroidogenic factor-1, 
to induce production of steroidogenic enzymes and stimulates the production 
of adrenal glucocorticoids. These inducible genes include cytochrome P450 
enzymes (CYP) CYP17, CYP21B and CYP11B1, which is the final and rate-
limiting enzyme in active glucocorticoid synthesis pathway (Li et al., 2004; 
Mueller et al., 2006) (Figure 5). Mouse adrenals do not express CYP17, and 
therefore some steps in the corticosteroid synthesis are replaced by 3β-
hydroxysteroid dehydrogenase (HSD). Therefore, the active glucocorticoid in 
humans is cortisol and in mice and other rodents is corticosterone. 
The anti-inflammatory mechanisms of glucocorticoids involve actions at every 
level of inflammation. Glucocorticoids act via the glucocorticoid receptor, a 
nuclear receptor which can, in addition to its function as a transcription 
factor, activate or inhibit other transcription factors and mediators of 
inflammation. They decrease signaling through cytokine and Toll-like 
receptors, T-cell receptor in T cells, and immunoglobulin E receptor in mast 
cells, dampening inflammatory responses and allergic reactions. 
Glucocorticoids reduce cytokine production by inhibiting the synthesis and 
activity proinflammatory transcription factors, like NF-κB, and by enhancing 
their breakdown. They reduce leukocyte recruitment by reducing chemokine 
production, adhesion molecule expression in vascular wall and inflammatory 
cells, and by decreasing vascular permeability. Finally, they can induce 
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apoptosis and affect the differentiation of lymphocytes, dendritic cells, 
macrophages and eosinophils. (Cain and Cidlowski, 2017) 
Due to their broad anti-inflammatory effects, synthetic glucocorticoids are 
used in pharmacologic treatment of various inflammatory conditions, like 
rheumatoid arthritis, asthma and IBD, as well as to suppress immune system 
after organ transplantation. Common synthetic glucocorticoids in 
pharmacological use include hydrocortisone, fluticasone, prednisone, 
dexamethasone and budesonide. Owing to their broad effects, glucocorticoid 
therapy causes a wide range of side effects, including hyperglycemia, 
osteoporosis, increased risk of infections, and mood changes, which limits 
their long-term use. However, dependence on glucocorticoid therapy, 
meaning inability to reduce glucocorticoid dose, is common in patients, and a 
small part of patients is resistant to the benefits of glucocorticoid therapy 
altogether. (De Iudicibus et al., 2011; Vandewalle et al., 2018).  
 
Glucocorticoids in the intestine 
Intestine expresses its own fully functional steroid synthesis network and is 
able to produce anti-inflammatory glucocorticoids to regulate immune 
homeostasis (Bouguen et al., 2015b; Cima et al., 2004; Sidler et al., 2011). In the 
intestine, glucocorticoids are produced at the base of the crypts (Atanasov et 
al., 2008; Huang et al., 2014), under the control of the transcription factor liver 
receptor homolog-1 (LRH-1), instead of steroidogenic factor-1 in the adrenals 
(Bouguen et al., 2015b; Mueller et al., 2007; Mueller et al., 2006). LRH-1 
induces the production of steroidogenic enzymes cholesterol side-chain 
cleavage enzyme, encoded by CYP11A1 gene, 11β-hydroxylase, encoded by 
CYP11B1, 3β-HSD and 11β-HSD (Bouguen et al., 2015b; Cima et al., 2004) 
(Figure 5). Unlike in adrenals, cAMP inhibits glucocorticoid synthesis in 
intestine, where it seems to be activated by protein kinase C (Mueller et al., 
2007). Intestinal glucocorticoid synthesis is stimulated by activation of cells of 
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innate and adaptive immune systems (Cima et al., 2004; Noti et al., 2010b). 
Acute inflammation stimulates T cells and macrophages to produce TNFα, 
which induces glucocorticoid synthesis in epithelial cells (Noti et al., 2010b). 
In chronic inflammation, however, TNFα activation of c-Jun and NF-κB 
inhibits glucocorticoid production by reducing Lrh-1 and Cyp11b1 expression in 
mice (Huang et al., 2014).  
The known functions of locally produced glucocorticoids in the intestine are 
still sparse, but they all involve anti-inflammatory regulation of immune 
system. Intestinal glucocorticoids are an important feedback mechanism in 
regulation of intestinal inflammation (Bouguen et al., 2015a; Coste et al., 2007). 
They can directly inhibit antigen-dependent activation of T-cells and promote 
apoptosis in them (Cima et al., 2004; Sidler et al., 2011). Intestinal 
glucocorticoids also contribute maintaining immune homeostasis by 
promoting the expression the anti-inflammatory and tolerogenic transcription 
factor, peroxisome proliferator activated receptor gamma (PPARγ) (Annese et 
al., 2012; Bouguen et al., 2015b). 
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Intestinal glucocorticoids in inflammatory bowel 
diseases 
As glucocorticoids are the key anti-inflammatory hormones, it is no surprise 
that perturbations in their local synthesis is involved in the pathogenesis of 
IBD in many ways. LRH-1, CYP11A1, CYP11B1, and HSD11B1 expression, and 
consequently the levels of glucocorticoids, are low in inflamed colon samples 
of IBD patients (Ahmed et al., 2019; Bouguen et al., 2015b; Coste et al., 2007). T 
cells in intestine are resistant to apoptosis in IBD patients, but the connection 
between low glucocorticoid production and aberrant T-cell activation has not 
been established. The deficiency in glucocorticoid production also leads to 
reduced expression of PPARγ (Bouguen et al., 2015b), which is implicated in 
UC pathophysiology and is the target of 5-aminosalicylic acid, an anti-
inflammatory drug used to treat IBD (Rousseaux et al., 2005). A single-
nucleotide LRH-1 polymorphism has been identified to be associated with UC 
(Jostins et al., 2012). One potential relationship of glucocorticoids and IBD 
pathophysiology involves endoplasmic reticulum (ER) stress, which is 
associated with IBD (Fritz et al., 2011). Inflammation and other stressors in 
secretory cells, like intestinal epithelial cells, result in overload of protein-
processing demand in the ER for its protein-folding capacity, and 
accumulation of unfolded proteins leads to ER stress, (Bouguen et al., 2015a; 
Fritz et al., 2011; Kaser et al., 2008). Glucocorticoids induce responses to 
augment protein folding and degradation during ER stress, thus relieving it 
(Das et al., 2013), but involvement of local glucocorticoid production has not 
been proven. 
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Interactions of renin-angiotensin system and 
glucocorticoids 
Glucocorticoids and renin-angiotensin system are linked in adrenals and 
vasculature in many ways. Glucocorticoids increase expression of ACE (Fishel 
et al., 1995; Mendelsohn et al., 1982) and AT1R (Sato et al., 1994; Shelat et al., 
1999) in various tissue types, including endothelium, vascular smooth muscle 
cells and leukocytes. Conversely, Ang II can induce and potentiate ACTH-
activated adrenal glucocorticoid synthesis (McKenna et al., 1978; Parker et al., 
1983; Spinedi et al., 1989). Although ACTH is the primary stimulating molecule 
of glucocorticoid synthesis, ACTH is only two to three times more potent 
activator than of Ang II (Pham-Huu-Trung et al., 1986).  
 
Glucocorticoids are anti-inflammatory steroid 
hormones which are produced centrally in adrenal 
cortex but also locally in intestine. Intestinal 
glucocorticoid synthesis is regulated differently from 
adrenals, and its roles include maintaining immune 
homeostasis by promoting immune tolerance and 
inhibiting immune activation. Disturbances in intestinal 
glucocorticoid synthesis are associated with inflamed 
lesions in inflammatory bowel diseases. 
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2.4 Mesenchymal stromal cells 
Mesenchymal stromal cells (MSCs) are multipotent stem cells, which possess 
immune-regulatory and anti-inflammatory properties. They are found in most 
tissues, including bone marrow, adipose tissue and umbilical cord, with the 
ability to differentiate into chondrocytes, osteoblasts and adipocytes (Dave et 
al., 2015). Upon activation, they can inhibit proinflammatory immune cell 
functions, like immune cell proliferation, maturation and migration as well as 
antigen presentation, and promote leukocyte differentiation towards anti-
inflammatory and regulatory functions (Gregoire et al., 2017). Promoting 
immune cell differentiation to regulatory T cells, dendritic cells and 
macrophages leads to reduction of proinflammatory cytokines and elevation of 
anti-inflammatory mediators, like IL-10 and indoleamine 2,3-dioxygenase 
(IDO), which further upregulate regulatory T cells and inhibit other T cells. 
Additionally, MSCs themselves secrete growth factors and immunosuppressive 
compounds, like PGE2, nitric oxide and TGFβ (Gregoire et al., 2017). MSCs 
migrate to sites of inflammation where they are activated by the various 
factors, including proinflammatory cytokines IL-1β, TNFα and IFNγ to reduce 
inflammation and promote tissue healing and survival. Without a 
proinflammatory stimulus, MSCs can assume a proinflammatory phenotype, 
which promotes immune cell recruitment and polarization to 
proinflammatory subtypes. Thus, MSCs support both the pro- and anti-
inflammatory functions of the host as needed. (Bernardo and Fibbe, 2013; Dave 
et al., 2015; Gregoire et al., 2017) 
 
Mesenchymal stromal cell therapy 
In addition to the anti-inflammatory and immunosuppressive properties of 
MSCs, they possess an unusual trait for being low in immunogenicity, which 
has made them a target of interest for allogenic cell therapy, in which the 
recipient receives donated cells from a third party. In fact, they were first 
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thought to be completely immune privileged, meaning they would not cause 
an immune reaction even when donor and host are not human leukocyte 
antigen matched, which would therefore enhance the safety of MSC therapy 
(Ankrum et al., 2014). However, recent studies have demonstrated an 
alternative mechanism for immune-suppression by MSCs, which requires host 
immune-cell reaction and subsequent phagocytosis of apoptotic MSCs to 
induce IDO production and immune cell differentiation towards regulatory 
types (de Witte et al., 2018; Galleu et al., 2017). In autologous cell transfer, the 
recipient is treated with their own cells and there are no similar immune 
reactions between host and transferred cells.  
Cell therapy using MSCs has been investigated as a treatment in regenerative 
medicine, and for various immunologic and inflammatory conditions like 
graft-versus-host disease and IBD (Ankrum and Karp, 2010). Either autologous 
and allogenic MSCs are typically harvested from bone marrow or adipose 
tissue and expanded in vitro before administration to the patient. Although 
MSCs possess the capacity to differentiate into different cell types, in cell 
therapy, the main therapeutic effect is thought to be facilitated by their ability 
for immune regulation. 
 
Mesenchymal stromal cells as a potential treatment for 
inflammatory bowel diseases 
Allogenic, from the same species, and xenogeneic, from a different species, 
MSCs have been studied in context of intestinal inflammation in preclinical 
studies. MSCs have been effective in treating DSS and TNBS colitis when using 
either untreated, i.e. not activated, murine MSCs (Chen et al., 2013a; He et al., 
2012; Sala et al., 2015; Tanaka et al., 2008; Wang et al., 2016; Xie et al., 2017) or 
human, i.e. xenogeneic, MSCs, which have been activated by IFNγ, IL-1β or 
Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) prior to 
administration (Duijvestein et al., 2011; Fan et al., 2012; Kim et al., 2013). Non-
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activated human MSCs have not as been effective in treating murine colitis 
(Duijvestein et al., 2011; Fan et al., 2012), likely due to lack of cross-reactivity 
between cytokines and their receptors between species (Galleu et al., 2017).  
MSCs have been studied in the treatment of refractory IBD in numerous 
clinical trials (Gregoire et al., 2017; Lightner et al., 2018; Qiu et al., 2017). Cell 
therapy can be administered either intravenously to treat luminal IBD or 
applied topically to treat fistulas in CD. Phase I and II clinical trials on treating 
luminal disease with bone-marrow derived MSCs have demonstrated a 
somewhat inconsistent benefit, but in general allogenic transfer of MSCs has 
been more efficient at reducing disease activity and inducing remission than 
autologous transfers (Duijvestein et al., 2010; Forbes et al., 2014; Hu et al., 2016; 
Liang et al., 2012; Qiu et al., 2017). Local administration of adipose-tissue or 
bone-marrow derived MSCs for treatment of fistulas have been efficient in 
achieving fistula closure in both autologous and allogenic transfers (de la 
Portilla et al., 2013; Garcia-Olmo et al., 2009; Lee et al., 2013; Lightner et al., 
2018; Molendijk et al., 2015; Panes et al., 2016). Alofisel™ (Panes et al., 2016) by 
TiGenix and Takeda, is the first MSC product  to gain marketing approval for 
treatment of fistulas in Crohn’s disease. At the moment, five trials are ongoing 
according to ClinicalTrials.gov for the treatment of fistulas in Crohn’s disease 
and one for the treatment of ulcerative colitis using MSC therapy, all of them 
employing local instead of systemic application of MSCs. The inconsistent but 
promising results gained in clinical trials underline the importance of 
investigating optimal culture and treatment protocols in MSC therapy. 
 
Glucocorticoids and renin-angiotensin system in 
mesenchymal stromal cell therapy 
RAS and glucocorticoids are general proinflammatory and anti-inflammatory 
mediators, respectively, and as such, immunosuppressive MSCs interact with 
them in the host and sense the inflammatory environment through 
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angiotensin and glucocorticoid receptors, in addition to classical cytokines.  In 
a radiation-induced proctitis model, MSCs were shown to increase colonic 
glucocorticoid production and express steroidogenic enzymes and produce 
glucocorticoids themselves (Bessout et al., 2014). Like activation by 
proinflammatory cytokines, pretreatment of MSCs with Ang II improved their 
beneficial effect in a model of myocardial infarction (Liu et al., 2015). On the 
other hand, microvesicles from MSCs were shown to downregulate the 
classical proinflammatory RAS and upregulate the alternative anti-
inflammatory RAS in a model of pulmonary hypertension, in which the 
beneficial effects were mediated by Mas receptor (Liu et al., 2018). 
 
Mesenchymal stromal cells are immunoregulatory cells 
with potential for immunomodulatory cell therapy due 
to their immunosuppressive and wound healing 
capacity, and their low immunogenicity. They have 
shown promise in the treatment of inflammatory bowel 
diseases, but optimal culture conditions and 
augmentation of MSC activation by cytokines and 
growth factors are under investigation in animal 
models. As the knowledge of involvement of renin-
angiotensin system and local glucocorticoids in the 
process of intestinal inflammation is emerging, their 
connections with mesenchymal stromal cells are being 
realized.  
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3 AIMS OF THE STUDY 
Renin-angiotensin system is involved in several aspects of inflammation and 
wound healing in the intestine. This thesis characterizes intestinal RAS during 
colitis, explores novel interventions for intestinal inflammation in preclinical 
studies with a link to the intestinal RAS, and investigates the possible role of 
RAS in regulation of glucocorticoid synthesis in the gut. All studies employ the 
DSS-induced colitis model in mice. In the first study (Study I), ACE shedding 
and glucocorticoid synthesis were localized in the inflamed gut. Associations 
between RAS and glucocorticoid synthesis were investigated in Studies I and 
II. Study III focused on examining and comparing how different RAS 
inhibitors could improve colitis. Safety and efficacy of mesenchymal stromal 
cell (MSC) therapy in DSS-induced colitis, and its effect on intestinal RAS 
were examined in Study IV. 
The specific aims of this study were to: 
? Test novel therapeutic interventions, inhibition of RAS by ACE 
inhibitors and angiotensin II receptor blockers and MSC therapy, for 
intestinal inflammation. (Studies III and IV) 
? Analyze how intestinal inflammation, pharmacologic and dietary 
inhibition of RAS, and MSC therapy affect intestinal RAS components. 
(Studies I, II, III and IV) 
? Investigate possible connections between local RAS and glucocorticoid 
synthesis in healthy and inflamed intestine. (Studies I, II and III) 
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4 MATERIALS AND METHODS 
4.1 Experimental animals 
BALB/c male mice aged 7-9 weeks were used in all the studies. The animals 
were obtained from the commercial breeders, Scanbur (Sollentuna, Sweden), 
for Studies I and III, and Envigo (formerly Harlan Laboratories) (Horst, 
Netherlands) for Studies II and IV. The animal experiments were approved by 
the National Animal Experiment Board of Finland (permits 
ESAVI/6314/04.10.03/2012 and ESAVI/114/04.10.07/2015). The mice were 
housed in pairs in a specific-pathogen free animal facility under a 12h/12h 
light/dark cycle at 22 ± 2 °C and 55 ± 15% humidity. They were given food 
(Teklad Global 18% Protein Rodent Diet, Harlan Laboratories) and drinks ab 
libitum.  In Study III, the mice were housed in individually-ventilated cages.  
 
4.2 Colitis models and study designs 
In all the studies, acute colitis was induced to the colitis groups by adding 3% 
or 5% (w/v) 40kDa DSS (TdB Concultancy, Uppsala, Sweden) to the drinking 
fluid of the mice for 6 to 7 days. Mice receiving tap water for the same 
duration were used as healthy controls. During the experiments, mice were 
weighed to assess the severity of colitis, and their condition were observed 
daily. 
The study designs are presented in Figure 6. In Study I, the effects of two 
different DSS concentrations were studied. The mice were divided into three 
groups and given either tap water or 3% or 5% DSS solution for 7 days, after 
which they were sacrificed for sample collection.  
The intervention studies (II, III and IV) entailed groups of healthy and DSS-
control mice with untreated colitis, and intervention groups receiving DSS and 
the test compounds to test the interventions' ability to alleviate colitis and 
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modulate intestinal RAS and glucocorticoid synthesis during intestinal 
inflammation. ACE inhibitors and ACE-inhibiting Ile-Pro-Pro were examined 
in Studies II and III. The test compounds (Table 4) were given in drinking 
water for 5 days before the introduction of DSS to acquaint the mice to the 
compounds, after which acute colitis was induced by adding 3% DSS to the 
drinking fluids containing the test compounds for another 7 days, and then 
sacrificed. In Study II, the mice received either tap water, 15.7 mg/l ACE 
inhibitor, captopril (PHR1307-1G, Sigma-Aldrich, St. Louis, MO, USA), or 833 
mg/l ACE-inhibiting peptide, Ile-Pro-Pro (H-4632, Bachem, Bubendorf, 
Switzerland), as test compounds.  
In Study III, the mice initially received either 11 mg/l ACE inhibitor, enalapril 
(PHR1289, Sigma Aldrich), 37 mg/l angiotensin II receptor blocker, losartan 
(PHR1602, Sigma Aldrich), or both for the first 5 days, after which the 
concentrations of enalapril and losartan were adjusted to 25 mg/l and 83 mg/l, 
respectively for the duration of the 7-day DSS challenge. The daily doses are 
presented in Table 4. The daily doses of medications were based on effective 
doses reported in publications of colitis studies (Jahovic et al., 2005; Lee et al., 
2014; Liu et al., 2016), except for Ile-Pro-Pro, which had not been investigated 
in colitis studies before.  
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Table 4. Conversions of concentration of compounds in drinking fluid to estimation of daily 
doses per animal and weight during DSS administration. The numbers in brackets indicate the 
initial doses in Study III. 
Study Treatment 
Dose 
mg/l mg/day mg/kg/day 
St
ud
y 
II
 Captopril 15.7 0.11 5 
Ile-Pro-Pro 0.833 5 227 
St
ud
y 
II
I Enalapril 25 (11) 0.075 (0.033) 3(1.3) 
Losartan 83 (37) 0.25 (0.11) 10(4.4) 
 
In Study IV, two separate animal experiments were conducted to test MSCs in 
acute colitis (Study IVa) and during tissue regeneration (Study IVb). Acute 
colitis was first induced to four groups of mice by administering 3% DSS for 7 
days (Study IVa). The colitis groups received either vehicle (0.9 % NaCl + 5% 
human serum albumin) or 0.5 x 106 freshly cultivated, meaning they were not 
frozen between their expansion and administration, human bone-marrow 
derived, platelet-lysate expanded MSCs in vehicle intraperitoneally or 
intravenously via the tail vein under isoflurane anesthesia on the 3rd and 5th 
days of DSS administration. To dilate the tail veins, the mice were kept in a 
warming cabinet at 37 °C for 5-10 minutes prior to inducing general anesthesia 
with isoflurane gas. The tails of the mice receiving intravenous injections were 
warmed on a heat pad while MSCs or vehicle were injected to the tail vein 
using a G30 needle. The animals were sacrificed after receiving DSS for 7 days.  
Next, colitis was induced for three additional groups with 3% DSS for 6 days, 
after which they received tap water for an additional 7 days to allow healing 
process to begin (Study IVb). The colitis groups received either vehicle (0.9% 
NaCl + 3.6% human serum albumin) or 0.5 x 106 freshly cultivated or 
cryopreserved, meaning frozen after expansion and thawed just before 
administration, MSCs intravenously. The MSCs were cultivated at Advanced 
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Cell Therapy Centre, Finnish Red Cross Blood Service. The treatment regimens 
are presented in Figure 6. 
 
Figure 6. Study designs and timelines of each study. Fresh MSCs = freshly cultivated MSCs, IV 
= intravenously, IP = intraperitoneally. 
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4.3 Macroscopic assessment of inflammation 
After sacrifice in Studies II, III and IV, colons were promptly excised and the 
lengths measured, and the typical manifestations of colitis were visually 
assessed. Stool consistency, tissue edema and visible blood were scored 
individually and summed as macroscopic scores. The scales were ranging from 
0 to 2 in each category in Study II and III as follows: stool consistency (0 = 
normal, 1 = loose and 2 = liquid), bleeding and edema (0 = none present and 2 
= clearly observable). In Study III, the scales were expanded so that stool 
consistency was scored on a scale of 0 - 4 (0 = normal, 1 = moist, 2 = loose, 3 = 
liquid, 4 = empty colon), and presence of blood (0 = none, 1 = streaks, 2 = 
clearly visible, 3 = heavy bleeding) and edema (0 = normal, 1 = mild, 2 = 
moderate and 3 = marked) on a scale of 0 - 3. 
 
4.4 Ex vivo-incubation sample preparation 
Intestinal incubation samples were prepared to quantify how much ACE was 
cleaved from intestinal samples and how much corticosterone was synthesized 
and secreted by intestinal epithelial cells. Sections of jejunum (Study I), ileum 
(Study III), proximal colon (Studies I, II and IV) or distal colon (Study III) were 
washed and incubated in pre-oxygenated Krebs buffer (119 mmol/l NaCl, 25 
mmol/l NaHCO3, 15 mmol/l KCl, 11 mmol/l Glucose, 1.6 mmol/l CaCl2, 1.2 
mmol/l KH2PO4, 1.2 mmol/l MgSO4, chemicals obtained from Sigma-Aldrich) 
for 5-10 min at room temperature to minimize serum contamination, and then 
incubated in Krebs buffer for another 90 min at 37 °C in gentle agitation. The 
incubation supernatant was centrifuged clear of debris and used in 
immunochemical analyses. In Study I, Ang II or captopril (Sigma-Aldrich) in 
final concentrations ranging from 0.1 – 10 μmol/l for Ang II and 1 – 100 μmol/l 
for captopril were added into the incubation media to study stimulation and 
inhibition of corticosterone synthesis. Analyte concentrations were related to 
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the wet weight (Study I) or protein concentration of the corresponding tissue 
piece (Studies II, III and IV). 
 
4.5 Histological assessment of inflammation 
Histopathological changes were assessed qualitatively in Study I in jejunum 
and colon. In studies II, III and IV, the histopathological damage in colon was 
assessed quantitatively. Gradings of inflammatory cell infiltration and 
epithelial erosion were performed in Study II on a scale of 0 – 3, each, 
according to Erben et al., 2014 (Erben et al., 2014) and on a scale of 0 – 5 each 
in Study IV. In studies III and IV, the analysis of the samples was performed by 
an expert pathologist who was blinded to the treatment of the study groups. 
In Study III, a detailed analysis of mucosal injury (including sub-scores of 
surface epithelial injury, crypt epithelial injury, and crypt dilatation and 
distortion) as well as inflammation (including sub-scores for the presence of 
granulocytes, lymphocytes and macrophages, and granulomas) was executed 
and each were graded on a scale of 0 – 9. 
 
4.6 Biochemical analyses 
Protein and hormone analytes were quantified using commercial assays 
according to manufacturers’ suggested protocols. ACE protein was measured 
in the ex vivo-incubation and tissue samples using Mouse ACE DuoSet ELISA 
(#DY1513, R&D System, Minneapolis, MN, USA) in all studies. Corticosterone 
concentration was measured in the ex vivo-incubation samples using 
Corticosterone EIA and ELISA kits (#500655 in Studies I, II and IV and #501320 
in Study III, Cayman Chemical, Michigan, MI, USA). IL-1β and TNFα protein 
concentrations were quantified in colon tissue using AlphaLISA Detection Kits 
(AL503 and AL504, Perkin Elmer, Waltham, MA, USA) in Studies II and III. 
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Protein content of the corresponding tissue pieces were quantified using 
Pierce™ BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 
 
4.7 Quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) 
RT-qPCR was used in studies II, III and IV to measure the gene expression of 
selected members of intestinal RAS and glucocorticoid synthesis. Messenger 
RNA (mRNA) was extracted from mid-distal colon segments using NucleoSpin 
RNA (#740955, Macherey Nagel, Düren, Germany). Reverse-transcription of 
mRNA into complementary DNA (cDNA) was done using iScript cDNA 
Synthesis Kit (#1708891, BioRad, Hercules, CA, USA). All primers except for 
Eef2 primers (Eissa et al., 2016) were designed using NCBI Primer Blast and 
ordered from Sigma-Aldrich (Sigma-Aldrich). RT-qPCR was run using 
LightCycler 480 SYBR Green I Master (Roche Diagnostics, Mannheim, 
Germany) and the LightCycler 480 equipment. Gene expression of target 
genes was normalized to the geometric mean of multiple reference genes β-
actin and S18 in Studies II and IV and Rplp0, S18, and Eef2 in Study III using 
calculations originally presented in Hellemans et al., 2007 (Hellemans et al., 
2007). The primer sequences used in this thesis are presented in Table 5. 
 
4.8 Statistical analysis 
Statistical analyses were conducted on either GraphPad Prism 5.0 (GraphPad 
Software, La Jolla, CA, USA) (Studies I and IV) or SPSS 22 and 23 (IBM, 
Armonk, NY, USA) (Studies II, III and IV). p-values lower than o.o5 were 
considered statistically significantly different. 
The data were analyzed for normality using Shapiro-Wilk test and Levene’s 
test for homogeneity of variances, when applicable, and parametric or non-
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parametric tests were chosen accordingly. Logarithmic transformations were 
applied when possible in order to conduct parametric tests.  
The differences between two groups were analyzed either with Student’s 
unpaired t-test or Mann-Whitney U test. Differences between multiple groups 
were analyzed using one-way ANOVA followed by Tukey’s (Studies III and IV) 
or Dunnet’s (Study II) post hoc test or Kruskal-Wallis test followed by Mann-
Whitney U test (Studies III and IV). Correlations were analyzed with either 
Pearson (Study I) or Spearman correlations (Study II). Weight development 
was analyzed using repeated measures ANOVA (Studies II, III and IV). p-
values lower than 0.05 were considered statistically significant. 
 
Table 5. A list of primer sequences for the genes and internal control genes analyzed in this 
thesis. 
 
Gene Forward primer Reverse primer 
Ace 5'-GCTGGAGGGTCTTTGATGGA-3' 5'-AGTCACCTTGGGATCTTGGC-3' 
Agt 5'-CTTCCAAGGAACGATGAGAGGTT-3' 5'-ACAGACACCGAGATGCTGTT-3' 
At1r 5'-CTGCTCTCCCGGACTTAACA -3' 5'-GCACTTGATCTGGTGATGGC-3' 
Lrh-1 5'-GCATGGGAAGGAAGGGACAA-3' 5'-CGCTGATCGAACTGAAGGGA-3' 
Cyp11b1 5'-GGAACCCACCATCAGTAAGGA-3' 5'-TCTTCCCTCACGCATGACAA-3' 
Il-1β 5'-CTCCAGCCAAGCTTCCTTGT-3' 5'-TCATCACTGTCAAAAGGTGGCA-3' 
β-actin 5'-CTGAATGGCCCAGGTCTGAG-3' 5'-AAGTCAGTGTACAGGCCAGC-3' 
Rplp0 5'-TAACCCTGAAGTGCTCGACA-3' 5'-GGTACCCGATCTGCAGACA-3' 
S18 5'-AACGAACGAGACTCTGGCAT-3' 5'-ACGCCACTTGTCCCTCTAAG-3' 
Eef2 5'-TGTCAGTCATCGCCCATGTG-3' 5'-CATCCTTGCGAGTGTCAGTGA-3' 
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5 RESULTS 
5.1 Interventions for treating experimental colitis 
Assessment of colitis severity and resolution 
The protocol for colitis induction was tested in study I using 3 and 5% DSS 
solution for 7 days. The animals fed and drank normally throughout the 
experiment and began manifesting signs of colitis, i.e. ruffled fur, diarrhea, 
and rectal bleeding, during the last few days of DSS administration. At the 
given regimens, colitis did not lead to hunched posture, an indication of 
serious pain, or lethality. In this study, 3% DSS did not disturb weight 
development of the mice, whereas 5% DSS caused weight loss and induction of 
Il-1β mRNA expression (unpublished data) in BALB/c mice (Figure 7). 
Induction of colitis was apparent with both DSS concentrations, due to 
marked and similar histopathological changes, including erosion, ulcerations, 
disrupted crypt structure, edema and inflammatory cell infiltrate (Figure 8).   
 
 
Figure 7. Weight development (n = 8 in each group) and colonic Il-1β mRNA expression (n = 5 
in each group) indicating a more severe colitis in 5% DSS group. * indicates p < 0.05 compared 
to healthy and # indicates p < 0.05 compared to 3% DSS. 
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Figure 8. Hematoxylin and eosin stained slides show the disruption of the mucosal structures 
in DSS colitis. 
 
Milder, 3% DSS-induced colitis was chosen for Studies II, III and IV to 
investigate interventions that could potentially alleviate colitis and modulate 
glucocorticoid synthesis. Colitis severity and its resolution was assessed by 
measuring the body weights of the animals and lengths of colons, grading 
macroscopic and histopathological inflammation, and quantifying protein or 
mRNA levels of IL-1β and TNFα. Macroscopic and histopathologic scores of 
colitis groups were consistently increased by DSS in all studies (Table 6). The 
histopathological changes in acute colitis included loss or deformation of 
crypts, erosion, ulceration, mucosal and submucosal inflammatory cell 
infiltrate, and appearance of granulomatous foci. Distinct surface and crypt 
epithelial cell hyperplasia were seen in regenerative phase of colitis (Study 
IVb). Macroscopic changes consisting of stool consistency, colonic edema and 
bleeding were present but in a varying degree. Colons of mice were shortened 
by DSS administration in Studies II and III. The weights of the mice developed 
somewhat differently between the studies even under the same colitis 
protocols. The weights of the animals receiving 3% DSS declined significantly 
in Study II and Study IVb but were not statistically significantly different 
compared to healthy controls in Study I, III and IVa. Proinflammatory 
cytokines, IL-1β and TNFα were prominently induced by DSS in Studies II and 
IV, and to a lesser degree in Study III. Induction of colitis was evident in each 
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study based on histopathological damage, macroscopic manifestations and 
proinflammatory cytokine levels. 
 
Enalapril and losartan alleviate colitis and reduce 
inflammatory infiltrate in lamina propria  
Both an ACE inhibitor enalapril and an angiotensin II receptor blocker
losartan alleviated colitis in Study III at doses of 3 and 10 mg/kg/d, 
respectively, by reducing inflammatory cell infiltrate and granulomatous foci 
in lamina propria of colon, which together accounted for the inflammation 
score (Table 6). Losartan, in addition, reduced macroscopic scores. The 
reduction could not be accounted for by any of the individual parameters 
(stool consistency, edema, bleeding), but rather the overall impression was 
milder in losartan group compared to DSS group. Enalapril completely 
suppressed the induction of colonic Il-1β mRNA expression (Figure 9). The 
combination of enalapril and losartan at the prementioned doses, or ACE 
inhibitor captopril at a dose of 5 mg/kg/d or Ile-Pro-Pro at a dose of 227 
mg/kg/d in Study II, did not improve colitis by the measured parameters.  
 
Xenogeneic mesenchymal stromal cells have a limited 
anti-inflammatory effect on colitis 
Mesenchymal stromal cell treatment was examined at two different 
timepoints of the inflammation process in Study IV (Figure 6). In acute phase 
of colitis in Study IVa, intravenously or intraperitoneally administered freshly 
cultivated MSCs did not improve body weight loss or macroscopic 
inflammation. Colonic IL-1β and TNFα protein levels were increased in mice 
receiving 3% DSS and vehicle for 7 days, and the increase of IL-1β was 
completely abolished by intravenously administered MSCs, indicating a slight 
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benefit (Figure 9). In the next part of the study (Study IVb) (Figure 6), body 
weight first declined in all colitis groups and begun to recover from day 10 to 11 
onwards. At the end of the experiment, colitis was still evident in colitis 
groups based on lower bodyweights, increased macroscopic and 
histopathology scores, shortening and increase of weight of colons relative to 
the body weight. Colonic IL-1β and TNFα protein and Il-1β mRNA levels were 
increased in mice receiving either vehicle or cryopreserved MSCs, but the 
increase of proinflammatory cytokines did not reach statistical significance in 
the group receiving freshly cultivated MSCs (Figure 9) Neither freshly 
cultivated nor cryopreserved MSCs improved body weight development, 
macroscopic scores, colon length or weight, histopathological damage, or 
levels of proinflammatory cytokines. 
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Table 6. Colitis severity in different studies. Colon lengths are presented as mean ± standard 
deviation and disease scores as median (Interquartile range). † p < 0.05 compared to healthy, * 
p < 0.05 and ** p < 0.01 compared to control. IVa acute and IVb regenerative phases of colitis, 
IP = intraperitoneally, IV = Intravenously. n = 8 – 10 in each group. 
       
Study Treatment Colon length 
(cm) 
Macroscopic 
score 
Histopathology 
score 
Injury score Inflammation 
score 
 
II Healthy 9.3 ± 0.3 0.0 (0.0) 0.0 (0.0)  
DSS 6.5 ± 0.5 † 3.5 (3.3) † 4.0 (3.0) †  
DSS + Captopril 6.0 ± 0.5 † 4.0 (2.0) † 4.0 (1.8) †  
DSS + Ile-Pro-Pro 5.6 ± 0.6 *† 4.0 (2.5) † 5.0 (1.8) †  
              
III Healthy 7.7 ± 0.9 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
 DSS 6.7 ± 0.6 5.0 (4.8) † 10.5 (6.5) † 5.5 (6.0) † 5.0 (1.5) †
 DSS + Enalapril 7.2 ± 0.7 4.5 (5.5) † 6.0 (5.8) *† 4.0 (3.5) † 2.0 (2.8) **†
 DSS + Losartan 7.0 ± 1.1 2.5 (4.3) *† 6.5 (8.1) † 4.0 (5.3) † 2.8 (2.8) *†
 DSS + Enalapril + Losartan 7.2 ± 0.5 5.0 (5.3) † 6.5 (8.3) † 4.0 (3.5) † 3.0 (4.8) †
              
 
IVa Healthy 7.2 ± 0.3 0.0 (0.0)  
DSS + VE IV 5.5 ± 0.2 † 2.5 (4.3)  
DSS + MSC IV 5.3 ± 0.1 † 3.0 (2.8) †  
DSS + VE IP 4.9 ± 0.2 † 4.0 (2.0) †  
DSS + MSC IP 4.9 ± 0.2 † 4.0 (1.0) †  
       
IVb Healthy 8.1 ± 0.3 0.0 (0.0) 0.0 (0.0)   
 DSS + VE 6.1 ± 0.3 † 2.0 (1.1) † 5.8 (2.5) †   
 DSS + Fresh MSCs 6.5 ± 0.3 † 2.0 (2.0) † 5.0 (2.5) †   
 DSS + Cryopreserved MSCs 6.5 ± 0.5 † 2.0 (2.5) † 7.0 (6.5) †   
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Figure 9. Proinflammatory cytokines. mRNA expression of Il-1β and Tnfα (two upper figures) 
in Study III, and protein levels (two lower figures) in Study IV. Values are relative to healthy 
mice. Asterix indicates p < 0.05 compared to healthy and cross p < 0.05 compared to 3% DSS 
group. n = 4 – 10 in each group. 
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5.2 Renin-angiotensin system in experimental colitis 
ACE shedding is induced by inflammation and is 
location dependent 
Basal shedding of ACE was readily detected in incubation samples of all 
studied parts of the intestine, which were proximal colon in Studies I, II and 
IVb and distal colon in Study III, jejunum in Study I, and ileum in Study III 
(unpublished data) (Figure 10). However, whether ACE shedding was induced 
by inflammation, was dependent on the concentration of DSS and localization 
in colon. An increase in ACE shedding was induced by 3% DSS colitis in distal 
colon (Study III). In proximal colon, 5% DSS administration caused a clear 
increase in ACE shedding, whereas the shedding was not affected by 3% DSS 
administration (Figure 10). In small intestine, 3% DSS induced an increase in 
ACE shedding in jejunum (Study I) but not in ileum (Study III). Differences in 
ACE shedding were not reflected in ACE tissue concentrations or gene 
expression (Figure 10 and 11), but they were quantified in mid and mid-distal 
colon, respectively.  
 
Ile-Pro-Pro and cryopreserved MSCs reduce ACE 
shedding 
ACE shedding was reduced compared to untreated animals in proximal colon 
by Ile-Pro-Pro (Study II) and cryopreserved MSCs (Study IV) (Figure 10), while 
the reduction by captopril or freshly cultivated MSCs showed only a tendency 
for lower values. Cryopreserved MSCs also reduced the tissue level of ACE 
protein, possibly indicating a feedback mechanism to reduce proinflammatory 
Ang II signaling. The reduction in ACE shedding could not be explained by 
changes in the gene expression of Ace as it was not changed by Ile-Pro-Pro or 
cryopreserved MSCs (Figure 11). 
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Figure 10. ACE protein shedding in colon (upper panel), small intestine (middle panel), and 
tissue levels in colon (lower panel) in different studies. Values are relative to healthy mice. 
Asterix indicates p < 0.05 compared to healthy and crosses p < 0.05 compared to 3% DSS 
group. n = 6 – 10 in each group. 
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Gene expression of renin-angiotensin system 
components is not influenced by acute colitis 
The colonic mRNA expression of angiotensinogen (Agt), Ace, At1r and At2r 
was compared between acute colitis and healthy intestine (Studies I, II and IV) 
and during the healing process (Study IVb, partly unpublished data). In 
general, genes of RAS components were expressed at similar levels in healthy 
and inflamed intestine in acute colitis, but the expression of Agt seemed to be 
increased (p = 0.071) in mice receiving 5% DSS (unpublished data, Study I) 
(Figure 11) During the regenerative phase, At1r expression was downregulated 
and Lrh-1 expression only seemed to be reduced. 
 
Captopril decreases colonic gene expression of Ace and 
Agt 
The effect of captopril (Study II), enalapril, losartan (Study III) and the ACE-
inhibiting peptide Ile-Pro-Pro (Study II) on mRNA expression of RAS 
components (Agt, Ace, At1r) was examined parallel to the resolution of colitis. 
Although expression of Ace or Agt were not induced by colitis, their 
expression was reduced by captopril compared to DSS group (Figure 11). 
Similar effect was not seen with enalapril, losartan or Ile-Pro-Pro, indicating 
that captopril could have additional mechanisms than ACE inhibition in 
colon.  
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Figure 11. Gene expression of the measured RAS components. Values are relative to healthy 
mice. Asterix indicates p < 0.05 compared to healthy and cross p < 0.05 compared to 3% DSS 
group. n = 5 – 7 in each group. 
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5.3 Glucocorticoid synthesis in gastrointestinal tract 
Colitis induces corticosterone synthesis in proximal 
colon 
The synthesis of corticosterone in tissue incubations was measured in each 
study. Like with ACE shedding, DSS-induced corticosterone synthesis was 
dependent on the studied section of colon. Corticosterone synthesis was 
induced in acute colitis by 3% and 5% DSS in proximal colon in Studies I and 
II (Figure 12), parallel to weight loss of the mice (Study II) and colon 
shortening. On the contrary, corticosterone synthesis was not increased by 3% 
DSS in distal colon in Study III, but at the same time, normal weight 
development and colon lengths indicated an overall milder colitis. When 
measured during the healing process in Study IVb, although lower weight and 
colon shortening indicated an ongoing inflammation, corticosterone 
production in proximal colon was not increased in mice treated with 3% DSS 
either. The changes in corticosterone synthesis were not reflected in the 
transcription factor Lrh-1 or the rate-limiting enzyme Cyp11b1 mRNA 
expression, which were measured in mid-distal colon.  
 
Angiotensin II induces corticosterone synthesis ex vivo 
Stimulation and inhibition of corticosterone synthesis was tested in vitro in 
Study I, using ex vivo small intestine incubations. Ang II induced 
corticosterone synthesis at the highest tested concentration of 10 μM in the 
incubation media, and the induction appeared dose dependent (Figure 12). 
Captopril alone did not inhibit basal corticosterone synthesis at tested 
concentrations. 
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Figure 12. Corticosterone production in different parts of colon (upper panel) and small 
intestine (middle panel) in different studies (n = 6 – 10 in each group), and in jejunum in the 
presence of different concentrations of Ang II or captopril (lower panel) (n = 5). Values are 
relative to healthy mice. Asterix indicates p < 0.05 compared to healthy group.  
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Inhibition of RAS in vivo does not affect corticosterone 
synthesis 
The ability of RAS inhibitors to modulate corticosterone synthesis during 
established inflammation was examined in vivo using ACE inhibitors captopril 
(Study II) and enalapril (Study III), angiotensin II receptor blocker losartan 
(Study III) and the ACE inhibiting tripeptide Ile-Pro-Pro (Study II). Captopril 
completely suppressed the gene expression of Cyp11b1 (Figure 13), but it did not 
affect corticosterone production ex vivo in colon incubations (Figure 12). 
Enalapril, losartan or Ile-Pro-Pro did not have a similar effect on Cyp11b1 
expression. None of the compounds inhibited corticosterone synthesis in vivo, 
despite the suppression of Cyp11b1 by captopril. Lrh-1 gene expression was 
similar in healthy and inflamed intestine. 
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Figure 13. Gene expression of Lrh-1 and Cyp11b1. Values are relative to healthy mice. Cross 
indicates p < 0.05 compared to 3% DSS group. n = 3 – 7 in each group. 
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6 DISCUSSION 
6.1 Interventions for treating experimental colitis 
This series of studies investigated treatments for intestinal inflammation in 
the mouse DSS model in BALB/c mice, with a focus on local intestinal renin-
angiotensin system. A mild to moderate severity colitis in BALB/c mice using 
3% DSS administration was chosen to avoid obscuring the therapeutic effects 
of the interventions by overly severe colitis. The study designs were devised to 
measure the magnitude of changes caused by colitis and to compare the 
effects of interventions on these parameters during colitis, but the effects of 
these interventions to healthy intestine are unknown. Histopathological 
changes and cytokine profile in DSS colitis share similarities with human 
ulcerative colitis (Chassaing et al., 2014; Perše and Cerar, 2012). Although they 
represent only a part of pathogenesis of human IBD, treatments for IBD also 
alleviate DSS colitis, making the model relevant for investigating treatments 
for intestinal inflammation (Melgar et al., 2008). BALB/c mice are more 
resistant to DSS colitis than the commonly used C57BL/6 strain (Melgar et al., 
2005), but their propensity for colitis resolution and Th2/Th17-polarized 
inflammation resembling ulcerative colitis make BALB/c mice suitable for 
studying interventions (Yang et al., 2017).  
 
The potential of RAS modulation as a treatment for 
intestinal inflammation  
The ability of RAS inhibition to prevent and alleviate colitis was tested in 
Study III by administering ACE inhibitor enalapril, angiotensin II receptor 
blocker losartan or their combination in drinking fluid along with 3% DSS. 
The results demonstrate, that oral administration of RAS inhibitors can be 
feasible and effective in prevention of experimental colitis. Of the drugs 
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tested, enalapril had the strongest anti-inflammatory effects at tested doses 
regarding improvement of histopathology and proinflammatory cytokine 
levels. Losartan improved histopathological inflammation and macroscopic 
manifestations of colitis without improving proinflammatory cytokine levels. 
This could mean, that at larger doses, losartan might be more efficient than 
enalapril at alleviating colitis. The results are in agreement with previous 
studies employing oral administration of enalapril and losartan at similar 
doses in murine DSS and TNBS colitis models, with findings that both drugs 
alleviated histopathological damage and losartan improved macroscopic 
inflammation (Lee et al., 2014; Liu et al., 2016). Captopril, in our hands, had no 
therapeutic effect, which might be due to both the low dose (5 mg/kg/d) and 
the more potent induction of colitis, although this is not completely 
consistent with previous studies reporting alleviation of colitis on rats on 
captopril doses as low as 0.1 mg/kg/d (Jahovic et al., 2005). Higher, 50 
mg/kg/d doses have also been beneficial (Wengrower et al., 2004).  
Captopril, enalapril and losartan are antihypertensive drugs and although we 
did not measure blood pressure of the animals, there are reports that similar 
doses that were used in our studies do not induce hypotension for 
normotensive animals (Diop-Frimpong et al., 2011; Harding et al., 1993). The 
doses used in preclinical studies by us and others (Jahovic et al., 2005; Lee et 
al., 2014; Liu et al., 2016) do not represent clinical dosing for human 
hypertension, but are larger than those, owing to the nature of the common 
colitis models which employ a severe short-term inflammation. Better 
approximation of effective doses and comparison to existing medications 
could be achieved in chronic colitis models, like the recurring low-dose DSS 
model. The active metabolites of enalapril and losartan have short half-lives, 
at least in humans, and administration of drugs in drinking fluid served to 
avoid repeated gavaging two to three times per day to ensure stable levels of 
drugs in the body throughout the day. Oral administration of RAS inhibitors 
in drinking fluid has been reported with losartan in TNBS model (Shi et al., 
2016) and valsartan in TNBS and DSS models (Santiago et al., 2008), but 
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enalapril has not been administered in drinking fluid in experimental colitis. 
We could show that co-administration of enalapril and losartan with DSS were 
effective in alleviating colitis.  
The new findings in these studies are that, firstly, the alleviation of colitis was 
specifically associated with reduction of inflammatory infiltrate, and secondly, 
combination treatment with the effective doses of losartan and enalapril were 
not beneficial nor synergistic in treating colitis. Reducing Ang II formation by 
other enzymes, like chymase, and simultaneous blocking of Ang II signaling 
should lead to effective inhibition of AT1R-mediated proinflammatory actions, 
and theoretically, more potent alleviation of colitis. Since this was not the 
case, the results imply that combination treatment does not bring added 
benefits over single medications in treatment of intestinal inflammation, but 
the underlying reason for the loss of benefit in combination treatment 
remained unsolved. For treatments with single drugs, the mechanism behind 
reduced inflammatory infiltrate could be due to inhibition of leukocyte 
homing. AT1R regulates expression of MAdCAM-1, an adhesion molecule, 
which is induced by intestinal inflammation and IBD (Briskin et al., 1997; 
Mizushima et al., 2010). MAdCAM-1 increases homing of T cells to inflamed 
intestine by binding to α4β7-integrin at T-cell surface (Berlin et al., 1993; 
Briskin et al., 1997). The role of intestinal RAS in leukocyte homing has been 
investigated in one study, which found that candesartan downregulated Ang II 
-mediated upregulation of MAdCAM-1 in an endothelial cell lines and AT1R 
knockout mice expressed MAdCAM-1 at lower quantities during colitis 
(Mizushima et al., 2010), but the effect of RAS inhibitors on MAdCAM-1 
expression has not been studied in wildtype animals. The relevance of 
downregulation of these adhesion molecules and reducing leukocyte 
attraction by RAS inhibitors in intestinal inflammation is highlighted by that 
antibodies blocking α4β7-integrin, vedolizumab, and the α4-subunit, 
natalizumab, are approved for treatment in IBD and MAdCAM-1 antibodies 
are under development (Duijvestein and D'Haens, 2019). A more general 
mechanism of alleviating inflammation in our study, and in line with the 
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downregulation of Il-1β mRNA expression, might be the actions of RAS 
inhibitors on proinflammatory leukocytes, which have been shown to increase 
production of proinflammatory cytokines in response to Ang II and inhibit 
their production in response to RAS inhibitors (Fukuzawa et al., 1997; Lapteva 
et al., 2002). 
 
Non-activated mesenchymal stromal cells a potential 
treatment for intestinal inflammation 
The feasibility and safety of human bone-marrow derived platelet-lysate 
expanded MSCs were examined in intestinal inflammation, along with 
comparison of administration routes, and freshly cultivated and cryopreserved 
MSC. The results suggest a mild anti-inflammatory effect of non-activated 
xenogeneic freshly cultivated MSCs in terms of reduced proinflammatory 
cytokine levels, but they were not able to improve histopathological damage 
or prevent weight loss. Non-activated human MSCs have not been as efficient 
as pre-activated MSCs in treating mouse DSS and TNBS colitis (Duijvestein et 
al., 2011; Fan et al., 2012; Kim et al., 2013), which is likely caused by incomplete 
reactivity between mouse and human cytokines and their receptors leading to 
insufficient MSC activation in mice (Chen et al., 2009; Galleu et al., 2017; 
Zachar et al., 2016). IFN-γ, specifically, is crucial to the development of DSS 
colitis (Ito et al., 2006) and an important inducer of MSCs’ anti-inflammatory 
functions but lacks species cross-reactivity (Bernardo and Fibbe, 2013). 
However, since cell therapies in clinical applications utilize non-activated 
MSCs, avoiding additional manipulation of MSCs is still appropriate in 
preclinical testing. Some activation of MSCs in our xenogeneic model could 
possibly have been achieved by other universal mechanisms like nitric oxide 
(Chen et al., 2015; Kankuri et al., 1999), hypoxia, and activation of Toll-like 
receptors by for example lipopolysaccharide (LPS) (Crisostomo et al., 2008; 
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Krampera, 2011; Najar et al., 2017), explaining the limited beneficial effect of 
MSCs.  
The cryopreserved MSC product used in our study differs from many MSC 
products used in clinical studies of IBD (Gregoire et al., 2017) in that it has 
been cultivated in human platelet lysate instead of fetal bovine serum, 
eliminating xenogeneic agents from the final product. It has already been used 
in clinical applications like treating graft-versus-host disease, with good 
response rate to the treatment (Salmenniemi et al., 2017), and our data 
indicates feasibility of use in treatment of intestinal inflammation. Although 
the beneficial effects were gained using freshly cultivated MSCs, the data does 
not support conclusions between the efficacy of freshly cultivated and 
cryopreserved MSCs, due to the overall mild therapeutic effect. Since 
beginning of this work, reports have been cautiously positive on the efficacy of 
non-activated MSCs in clinical trials treating human IBD (Dave et al., 2015; 
Gregoire et al., 2017; Qiu et al., 2017), which encourages continuing 
investigations these MSCs in clinical studies of IBD, as well. 
We found that MSCs downregulate colonic ACE and subsequently its 
shedding, which could be taken as a beneficial response to the anti-
inflammatory actions of MSCs as Ang II induces NF-κB in various tissues 
(Suzuki et al., 2003). On the other hand, activation of NF-κB induces ACE and 
AT1R expression (Nishida et al., 2011; Shorning et al., 2012), so downregulation 
of ACE might be a consequence of reduced NF-κB activation, although this 
would need to be verified. Recent studies have shown, that microvesicles from 
MSCs downregulate Ace and upregulate Ace2 gene expression, consequently 
lowering Ang II to Ang 1-7 ratio, in a model of pulmonary arterial hypertension 
(Liu et al., 2018), and that MSCs downregulate ACE protein expression in a 
renovascular hypertension model in kidney (Lira et al., 2017; Oliveira-Sales et 
al., 2013). As far as we know, we are the first to show that MSCs downregulate 
ACE in intestine. 
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6.2 Renin-angiotensin system in intestinal 
inflammation 
ACE shedding is increased by inflammation 
This series of studies demonstrate, for the first time in intestine, a specific 
induction of ACE protein solubilization, ACE shedding, by inflammation. The 
induction of ACE shedding arguably parallels at least moderate inflammation, 
as DSS colitis has a strong tendency for increasing damage of intestinal 
mucosa from proximal towards distal colon. This would explain why ACE 
shedding was induced only in distal colon in 3% DSS-induced colitis, whereas 
the shedding by 5% DSS was induced in more proximal segment of colon as 
well. We also saw an increase in shedding in jejunum by 3% DSS but the 
reason for lack of dose-dependency of DSS is unsolved. Shedding of ACE in 
intestine by inflammation is in line with studies reporting increased plasma 
ACE concentrations in sepsis and lung injury in human patients (Orfanos et 
al., 2000; Votta-Velis et al., 2007), suggesting that ACE shedding is a universal 
mechanism in inflammatory conditions. 
The origin of solubilized ACE in intestine is unknown. In healthy colon, ACE 
is localized in vascular endothelium and to a degree in epithelium, but many 
immune cells carry ACE protein at their surface (Chen et al., 2013b; Danilov et 
al., 2003). There are reports of elevated ACE protein expression in pathological 
conditions, including DSS colitis (Spencer et al., 2007) and in human 
colorectal carcinoma, where ACE was localized at the apical surface of 
epithelial cells (Rocken et al., 2007), and in intraepithelial lymphocytes in a 
model of short bowel syndrome (Wildhaber et al., 2005). We could not 
corroborate the increase or depletion of ACE, either on protein or mRNA level, 
in mild to moderate DSS-colitis.  
Many surface proteins, like cytokines, are cleaved from cell membranes to 
elicit their paracrine effects, but virtually nothing is known about the 
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physiological function of ACE shedding. So far it is known that basal and 
induced shedding of ACE are differentially regulated and executed 
(Balyasnikova et al., 2002; Kohlstedt et al., 2004; Kohlstedt et al., 2002), and 
now we show that colitis increases ACE shedding in colon. Intuitively, the 
consequence could be that by shedding ACE, the proinflammatory Ang II 
production is reduced locally in the colonic mucosa, although the fact that 
ACE remains active post-cleavage indicates additional functions, like perhaps 
increasing the concentration of local Ang II in tissues where the soluble ACE is 
transferred. Alternatively, as retention of ACE at the cellular membrane is 
associated with activation of ACE signaling (Fleming, 2006), increased ACE 
shedding could be a way to downregulate its signaling function. 
 
RAS genes are not induced in mild to moderate colitis 
The genes of RAS or tissue-bound ACE protein were not induced by acute 
colitis, which is in contradiction with reports of increased ACE and AT1R 
protein levels and At1r mRNA expression in colonic epithelium in DSS model 
(Katada et al., 2008; Okawada et al., 2016; Spencer et al., 2007). The differences 
might be explained by the relatively mild colitis in our series of studies, or by 
strain differences, as all the aforementioned studies were conducted using 
C57BL/6 mice, which are more susceptible to DSS colitis (Melgar et al., 2005). 
On the contrary, during the healing process of colitis, our results show a 
specific downregulation of At1r gene expression, which could be assumed to be 
a feedback mechanism to inflammation and elevation of Ang II.  
 
ACE inhibitors are not alike 
We found that, unlike enalapril, losartan, or Ile-Pro-Pro, captopril 
downregulated Ace, Agt and Cyp11b1 expression, implying that captopril has 
additional mechanisms of action than merely ACE inhibition in the intestine.  
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This is in agreement with a report that captopril can downregulate ACE gene 
expression in human dendritic cells (Lapteva et al., 2002), but contradicts with 
findings that other ACE inhibitors, ramiprilat and perindoprilat, increase Ace 
expression in vitro and in vivo in vascular endothelial cells (Kohlstedt et al., 
2004). The reduction of Ace expression in our study was not fully reflected in 
ACE shedding, which was not significantly reduced in colon. 
Effects of Ile-Pro-Pro on gene and protein expression were tested alongside 
captopril, and their effects on ACE protein and gene expression were different. 
Ile-Pro-Pro reduced ACE shedding without affecting the gene expression of 
Ace, Agt or Cyp11b1, supporting the assumption that RAS inhibiting 
compounds have different modes of action. The reduction of ACE shedding by 
Ile-Pro-Pro is a novel finding, but due to the lack of available comparison, as 
blood pressure studies using Ile-Pro-Pro generally have not reported plasma 
ACE concentrations, the mechanism can only be speculated. It could be 
related to locking ACE to a more stable conformation or be mediated by other 
enzymes and receptors entirely, but reduced ACE protein expression cannot 
be excluded based on our data. Ile-Pro-Pro can modulate activity of other 
enzymes, like activate cathepsin G, which forms Ang II from Ang I (Klickstein 
et al., 1982), and inhibit prolyl oligopeptidase, which forms Ang 1-7 from Ang I 
and Ang II (Welches et al., 1993), and arginase at high concentrations 
(Lehtinen et al., 2010; Siltari et al., 2012), thus confounding its effect on RAS in 
vivo, but offer no explanation on the results of ACE shedding. Ile-Pro-Pro 
shares structural similarities with the natural activator of ACE signaling, 
bradykinin, also capable of retaining ACE on the cell membrane (Kohlstedt et 
al., 2002), in that they both contain a double-proline motif. Ile-Pro-Pro might 
retain ACE on the cell surface by activation of ACE signaling, which was 
reported also in the case of ACE inhibitors ramiprilat and perindoprilat 
(Kohlstedt et al., 2004), but without data on ACE phosphorylation status, this 
assumption remains speculative. Whether the effects of captopril and Ile-Pro-
Pro on intestinal RAS are specific to inflammatory conditions or if they apply 
to healthy intestine as well, cannot be concluded based on our results. 
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Contrary to the effects of captopril and Ile-Pro-Pro, enalapril had no effect on 
ACE expression or shedding, which further highlights the differences between 
ACE inhibitors. 
 
6.3 Glucocorticoids of the intestine 
Acute inflammation in the intestine induces colonic synthesis of anti-
inflammatory glucocorticoids (Coste et al., 2007). Since RAS activation is 
involved in intestinal inflammation, we wanted to study the involvement of 
RAS in glucocorticoid production in the intestine. Corticosterone synthesis 
was measured as the release of corticosterone from ex vivo incubated intestinal 
samples during a time course which was tested to yield differences between 
healthy and colitic mice (90 minutes) before reaching the full capacity of 
synthesis (at 3 hours) to avoid confounding effects of tissue degradation. As 
steroid hormones are lipophilic, they cannot be stored inside the cells, but are 
synthesized at demand, and therefore, the measured corticosterone in the 
sample can be assumed to be produced in situ.  
 
Induction of glucocorticoid synthesis requires at least 
moderate inflammation and might be location 
dependent 
The synthesis of corticosterone was induced in proximal colon by acute colitis, 
but it was not associated with increased expression of steroidogenic genes, 
Lrh-1 and Cyp11b1. With the rationale that histopathological damage in DSS 
colitis increases towards distal colon (Perše and Cerar, 2012), corticosterone 
production was measured in distal colon in the study investigating enalapril 
and losartan. However, then DSS failed to induce corticosterone synthesis or 
gene expression above baseline. The results could be interpreted in two 
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different ways. Either the induction of colonic corticosterone synthesis 
requires at least moderate to severe inflammation, as the colitis was overall 
milder in the last study, or that corticosterone production is not uniform 
across colon, but rather takes place in certain segments of the intestine. The 
latter is supported by our previous results that corticosterone production is in 
fact much more prominent in the small intestine than in colon, and the level 
of synthesis decreases gradually from duodenum to ileum (Mattila et al., 2016).  
In the experiments that glucocorticoid synthesis was induced (Studies I and 
II), Lrh-1 and Cyp11b1 mRNA were not increased by colitis. Activation of 
transcription factor LRH-1 is regulated by post translational modifications, like 
phosphorylation and ligand binding (Fernandez-Marcos et al., 2011), whereas 
steroidogenic enzymes are mainly regulated by transcription and availability 
of substrates (Hanukoglu, 1992). Induction of intestinal Cyp11b1 has been 
reported alongside increased glucocorticoid synthesis in DSS and TNBS colitis 
studies in C57BL/6 mice (Ahmed et al., 2019; Coste et al., 2007; Noti et al., 
2010a). Induction of Lrh-1, on the other hand, seems to require substantial 
provoking of the immune system with agents like LPS or T-cell activating 
antibodies (Mueller et al., 2006; Noti et al., 2010b). TNFα is a critical activating 
signal for intestinal glucocorticoid synthesis (Noti et al., 2010a), and its 
induction paralleled induction of glucocorticoid synthesis in Study II, but 
neither was induced in Study III. The choice of mouse strain is likely to affect 
intestinal glucocorticoid synthesis, as BALB/c mice are more resistant to DSS 
colitis than C57BL/6 mice, and their immunological response to colitis is 
polarized towards Th2 phenotype, instead of Th1 like in C57BL/6, leading to 
lower TNFα induction (Yang et al., 2017). Together this supports the 
assumption, that at least moderate induction of colitis is required to trigger 
intestinal glucocorticoid synthesis, as seen in the differences between our 
studies, and that the basal steroidogenic enzyme production is sufficient to 
increase glucocorticoid synthesis upon inflammatory stimuli without 
induction of Cyp11b1. However, since active glucocorticoids can be produced 
by 11β-HSD enzyme by conversion of 11-dehydrocorticosterone to 
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corticosterone in mice, an alternative synthesis pathway converting inactive 
adrenal-derived 11-dehydrocorticosterone to active corticosterone in colon 
cannot be ruled out based on our data.  
 
Ang II induces glucocorticoid synthesis in jejunum 
Ang II production is increased in colonic mucosa during experimental colitis 
(Khajah et al., 2016), and we wanted to test if Ang II participates in 
upregulation of intestinal corticosterone synthesis. Due to the limited size of 
mouse colon and the large amount of tissue needed, and because there are no 
indications that small and large intestine glucocorticoid synthesis would be 
differentially regulated (Bouguen et al., 2015a), the experiment was performed 
using small intestine samples. Pieces of mid jejunum were incubated in several 
concentrations of Ang II and the results show that Ang II can increase 
intestinal corticosterone synthesis in vitro. This has not been previously shown 
in the intestine, but Ang II has similar effects in adrenal zona fasciculata 
(McKenna et al., 1978; Parker et al., 1983; Spinedi et al., 1989). Regulation of 
adrenal and intestinal glucocorticoid synthesis are different in several ways. 
ACTH and steroidogenic factor-1 do not activate glucocorticoid synthesis in 
intestinal epithelium like they do in adrenals, which is instead in intestine 
under regulation of transcription factor LRH-1 (Coste et al., 2007). An 
intestine-specific peptide hormone which would increase glucocorticoid 
production has not been identified, but TNFα is required for intestinal 
glucocorticoid synthesis (Noti et al., 2010a), whereas it is a negative regulator 
of adrenal glucocorticoid synthesis (Jaattela et al., 1991; Villar et al., 2013). Our 
results suggest that intestine and adrenals, however, share similarities in Ang 
II-mediated induction of glucocorticoid synthesis. Upregulation of 
corticosterone by the generally proinflammatory Ang II suggests a feedback 
loop to regulate inflammation, and thus a new anti-inflammatory property for 
Ang II. Since it is established that Ang II induces TNFα in many cell types 
(Rosa et al., 2012; Sriramula and Francis, 2015), we propose a possible pathway 
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in which an inflammation-induced Ang II promotes glucocorticoid synthesis 
via TNFα in the intestine. Incidentally, parallel induction of colonic TNFα and 
corticosterone was observed in our studies, but the involvement of Ang II 
needs to be verified.  
 
RAS inhibitors do not modulate glucocorticoid 
synthesis in vitro or in vivo.   
As Ang II could induce glucocorticoid production in small intestine in vitro, 
we wanted to investigate the consequences of RAS inhibition on intestinal 
glucocorticoid synthesis. Basal glucocorticoid production could not be 
inhibited by captopril in vitro, implying that captopril does not affect the 
activity of LRH-1 or the steroidogenic enzymes in glucocorticoid synthesis 
pathway in healthy intestine. We next investigated whether RAS inhibitors 
could modulate colitis-induced glucocorticoid synthesis in vivo, and 
administered ACE inhibitors captopril and enalapril, angiotensin II receptor 
blocker losartan and ACE-inhibiting Ile-Pro-Pro in animals receiving DSS. 
Glucocorticoid synthesis was induced in the study using captopril and Ile-Pro-
Pro, but while neither of the compounds modulated glucocorticoid production 
nor gene expression of Lrh-1, captopril virtually abolished Cyp11b1 expression, 
offering some support to the involvement of RAS in regulation of intestinal 
glucocorticoid synthesis. There are no other reports of the effects of RAS 
inhibitors on intestinal steroidogenesis as far as we know, but some studies 
have evaluated their effects on adrenal corticosterone synthesis in rats. In one 
study, captopril had no effect on Cyp11b1 expression in adrenals (LeHoux and 
Tremblay, 1992), but in other studies intracerebroventricular captopril 
administration reduced plasma corticosterone (Berecek et al., 1988), and 
ramipril and candesartan reduced plasma corticosterone, but only when 
stimulated with corticotropin-releasing hormone (Raasch et al., 2006). When 
we tested enalapril and losartan alone or in combination, they had no effect 
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on intestinal glucocorticoid synthesis or gene expression in vivo, but the lack 
of induction of glucocorticoid synthesis by DSS in that study is a major 
confounding factor in regard of comparison of the RAS inhibitors. Put 
together, inhibition of RAS does not seem to modulate the inflammation-
induced corticosterone synthesis in the intestine, but our results indicate that 
RAS inhibitors might be different in regard of their ability to modify 
steroidogenic gene expression. 
 
6.4 Future aspects and clinical relevance 
As the pathogenesis of IBD involves both very general and very specific 
pathways, they are difficult and costly to treat with medications due to adverse 
effects and drug resistance. New treatment options are needed.  
Due to the broad physiological and pathophysiological roles of intestinal RAS, 
the effects of RAS inhibitors on intestinal inflammation are pleiotropic and 
complex, and thus there is likely no simple explanation on the beneficial 
response to colitis. In part, it may be due to reduced proinflammatory factors, 
reduced motility and maintaining fluid homeostasis thus alleviating diarrhea, 
reduction in leukocyte adhesion, reduced scarring and control of apoptosis 
and proliferation (Bernstein et al., 2013; Fishlock and Gunn, 1970). To date, 
there is convincing evidence that RAS is involved both in human IBD and 
experimental colitis (Garg et al., 2015c; Hume et al., 2016; Jaszewski et al., 1990; 
Khajah et al., 2016; Shi et al., 2016), and that inhibiting RAS activation provides 
beneficial anti-inflammatory effects in experimental colitis (Jahovic et al., 
2005; Liu et al., 2016; Spencer et al., 2007). The safety of RAS inhibitors has 
been demonstrated in treatment of cardiovascular diseases, they are 
inexpensive, readily available and lack the immunogenicity of new biologic 
medications, while affecting the same biological processes as current IBD 
medications (Hume and Radford-Smith, 2008). The feasibility and efficacy of 
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ACE inhibition or angiotensin II receptor blockade as a treatment for human 
IBD still needs to be investigated.  
MSCs are advanced therapy medicinal products, which are emerging as a new 
kind of treatment for IBD. Cell-based treatments are complex both in their 
function and manufacturing, and slow to emerge in general use. The first MSC 
product (Panes et al., 2016), Alofisel™, by TiGenix and Takeda has been 
approved for marketing in 2018 for treatment of complex perianal fistulas in 
Crohn’s disease in Europe, but none has yet been approved for luminal 
disease. Several trials are ongoing according to ClinicalTrials.gov.  
The studies in this thesis are all preclinical in nature, and their results 
encourage to continue investigations of RAS inhibitors and MSCs in the 
treatment of intestinal inflammation. They provide new information of RAS in 
intestinal inflammation, specifically of the induction of ACE shedding by 
colitis. Correlation of inflammation severity and ACE shedding and 
comparison of the phenomenon in different experimental colitis and in vitro 
models would clarify the pathophysiological regulation of ACE shedding. We 
found evidence that RAS participates in the regulation of glucocorticoid 
synthesis in intestine, which should be verified in colon and in vivo, for 
example by measuring mucosal Ang II levels or in Ang II infused animals, and 
prompts lucrative questions of the potential interactions of the anti-
inflammatory glucocorticoids and proinflammatory classical RAS in intestinal 
inflammation.  
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7 CONCLUSIONS 
This series of studies investigated new potential treatments for intestinal 
inflammation using inhibitors of renin-angiotensin system, and mesenchymal 
stromal cells, analyzed changes brought by colitis in intestinal renin-
angiotensin system and glucocorticoid synthesis, and examined their 
interactions particularly in a setting of intestinal inflammation. The 
conclusions based on the key findings of this thesis are: 
? Inhibition of renin-angiotensin system by enalapril or losartan alleviates 
DSS-induced colitis non-synergistically by reducing inflammation in the 
colon, encouraging investigations of RAS inhibition in clinical studies of 
human inflammatory bowel diseases.  
? Platelet-lysate expanded mesenchymal stromal cells are feasible in the 
treatment for intestinal inflammation, but although efficacy of 
treatment was modest in a xenogeneic model, they too have potential to 
be studied in clinical setting. 
? These studies revealed, for the first time, a specific induction of ACE 
shedding by intestinal inflammation, which paralleled the severity of 
colitis based on more prominent shedding in distal colon, the most 
affected location in DSS-colitis, and by increased DSS concentration. 
The ACE-inhibiting peptide, Ile-Pro-Pro, and mesenchymal stromal 
cells reduced ACE protein expression and shedding, which all together 
implies that cell surface proinflammatory ACE is actively regulated by 
shedding of the protein.  
? Ang II was found to induce intestinal corticosterone synthesis in vitro, 
whereas inhibition of ACE or angiotensin II receptor blockade did not 
affect glucocorticoid synthesis in vitro or in vivo. This implies that RAS 
activity participates in regulation of intestinal glucocorticoid 
production, thus revealing an indirect anti-inflammatory property of 
Ang II. We suggest the mechanism of Ang II upregulating 
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glucocorticoid synthesis would be via TNFα, which is a known inducer 
of intestinal glucocorticoid synthesis. 
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